{"content":"<li class=\"n-box-item date-title\" data-end=\"1495079999\" data-start=\"1494993600\" data-txt=\"Monday, December 23, 2019\">Wednesday, May 17, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3268317\" data-ts=\"1495075489\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268317-report-intel-denies-story-of-license-deal-amd\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Intel denies story of license deal with AMD</a></h4><ul>   <li>Intel (<a href=\"http://seekingalpha.com/symbol/INTC\" target=\"_blank\">INTC</a> <font color='red'>-2.2%</font>) has thrown cold water on the report that it would license graphics technology from <a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>, with a straight-up denial.</li>    <li><a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> (whose stock <font color='red'>fell 12.2%</font> today) had <a href=\"https://seekingalpha.com/news/3267962-amd-declines-comment-intel-license-report-unveils-epyc-server-chip\" target=\"_blank\">refused to comment</a> on a report by Fudzilla. But Intel tells Tiernan Ray \"The recent rumors that Intel has licensed AMD's graphics technology <a href=\"http://www.barrons.com/articles/intel-refutes-rumor-of-licensing-amd-graphics-technology-1495064908\" target=\"_blank\">are untrue</a>.\"</li>    <li>Fudzilla had said it was <a href=\"https://seekingalpha.com/news/3267815-amd-plus-7-percent-report-intel-will-license-graphics-chips\" target=\"_blank\">confirming the licensing deal</a>, which it suggested was a logical result of the expiration of Intel's deal with Nvidia (<a href=\"http://seekingalpha.com/symbol/NVDA\" target=\"_blank\">NVDA</a> <font color='red'>-6.6%</font>). AMD's stock <font color='green'>rose 11.7%</font> yesterday.</li>    <li>In the postmarket session tonight: <a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+0.5%</font>; <a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a> <font color='green'>+0.2%</font>; <a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='green'>+0.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268317\" data-linked=\"Report: Intel denies story of license deal with AMD\" data-tweet=\"$AMD $AMD $INTC - Report: Intel denies story of license deal with AMD https://seekingalpha.com/news/3268317-report-intel-denies-story-of-license-deal-amd?source=tweet\" data-url=\"https://seekingalpha.com/news/3268317-report-intel-denies-story-of-license-deal-amd\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>100&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268316\" data-ts=\"1495074508\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268316-petrobras-vale-plunge-brazil-president-reportedly-discussed-hush-money\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras, Vale plunge as Brazil president reportedly discussed hush money</a></h4><ul>     <li>Petrobras (NYSE:<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a>) <font color='red'>-11%</font> and Vale (NYSE:<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a>) <font color='red'>-7%</font>&nbsp;AH following a report that Brazil's Pres. Temer was taped <a href=\"http://www.reuters.com/article/us-brazil-corruption-idUSKCN18D2XY\" target=\"_blank\">approving the payment of a bribe</a> as part of the country's ongoing corruption probe.</li>     <li>The <em>O&nbsp;Globo</em> newspaper cites plea bargain testimony of a top businessman discussing with Temer a hush money payment to keep the jailed former House Speaker from testifying in the investigation.</li>     <li>ETFs: <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a>, <a href='https://seekingalpha.com/symbol/BRF' title='VanEck Vectors Brazil Small-Cap ETF'>BRF</a>, <a href='https://seekingalpha.com/symbol/BRZU' title='Direxion Daily Brazil Bull 3x Shares ETF'>BRZU</a>, <a href='https://seekingalpha.com/symbol/EWZS' title='iShares MSCI Brazil Small-Cap ETF'>EWZS</a>, <a href='https://seekingalpha.com/symbol/BZQ' title='ProShares UltraShort MSCI Brazil Capped ETF'>BZQ</a>, <a href='https://seekingalpha.com/symbol/BRAQ' title='Global X Brazil Consumer ETF'>BRAQ</a>, <a href='https://seekingalpha.com/symbol/BRAZ' title='Global X Brazil Mid-Cap ETF'>BRAZ</a>, <a href='https://seekingalpha.com/symbol/UBR' title='ProShares Ultra MSCI Brazil Capped ETF'>UBR</a>, <a href='https://seekingalpha.com/symbol/DBBR' title='Deutsche X-trackers MSCI Brazil Hedged Equity ETF'>DBBR</a>, <a href='https://seekingalpha.com/symbol/FBZ' title='First Trust Brazil AlphaDEX ETF'>FBZ</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3268316\" data-linked=\"Petrobras, Vale plunge as Brazil president reportedly discussed hush money\" data-tweet=\"$PBR $PBR $VALE - Petrobras, Vale plunge as Brazil president reportedly discussed hush money https://seekingalpha.com/news/3268316-petrobras-vale-plunge-brazil-president-reportedly-discussed-hush-money?source=tweet\" data-url=\"https://seekingalpha.com/news/3268316-petrobras-vale-plunge-brazil-president-reportedly-discussed-hush-money\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268306\" data-ts=\"1495060877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268306-stifel-reiterates-buy-on-square-after-dorsey-meeting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel reiterates Buy on Square after Dorsey meeting</a></h4><ul>   <li>Stifel has reiterated its Buy on Square (<a href=\"http://seekingalpha.com/symbol/SQ\" target=\"_blank\">SQ</a> <font color='red'>-3.8%</font>) and raised its price target after a confidence-boosting analyst meeting with founder Jack Dorsey.</li>    <li>Dorsey outlined <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9479731/jack-dorseys-top-priorities-for-square\" target=\"_blank\">three areas of focus</a> for the company: integrating Square's services more cohesively; automating more services like onboarding and predictive support; and making services more modular.</li>    <li>Square noted that it has less than 3% share of a $26B adjusted revenue opportunity in U.S. payments, analyst Scott Devitt notes. &ldquo;The company estimated the total addressable market of its entire commerce ecosystem (U.S. payments, eCommerce, software, Square Capital, and Caviar) is over $60 billion.&rdquo;</li>    <li>Devitt boosted his price target to $23 from $21, implying 17.6% upside from today's close.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268306\" data-linked=\"Stifel reiterates Buy on Square after Dorsey meeting\" data-tweet=\"$SQ - Stifel reiterates Buy on Square after Dorsey meeting https://seekingalpha.com/news/3268306-stifel-reiterates-buy-on-square-after-dorsey-meeting?source=tweet\" data-url=\"https://seekingalpha.com/news/3268306-stifel-reiterates-buy-on-square-after-dorsey-meeting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268305\" data-ts=\"1495060521\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLYC\" target=\"_blank\">GLYC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268305-glycomimetics-drug-candidate-gets-fda-breakthrough-therapy-designation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GlycoMimetics drug candidate gets FDA Breakthrough Therapy designation</a></h4><ul>     <li>GlycoMimetics (NASDAQ:<a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a>) <font color='green'>+35.9%</font> AH after saying it <a href=\"https://seekingalpha.com/pr/16836642-glycomimetics-gmiminus-1271-receives-fda-breakthrough-therapy-designation-adult-relapsed\" target=\"_blank\">received FDA Breakthrough Therapy designation</a> to its GMI-1271 drug candidate for treatment of adult relapsed/refractory acute myeloid leukemia.</li><li>GLYC believes GMI-1271 when combined with chemotherapy has the potential to address an  unmet therapeutic need for patients with AML.</li><li>The combination is currently being evaluated in the Phase 2 portion of a Phase 1/2 clinical trial in patients with AML, and GLYC says it is encouraged by clinical results so far.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268305\" data-linked=\"GlycoMimetics drug candidate gets FDA Breakthrough Therapy designation\" data-tweet=\"$GLYC - GlycoMimetics drug candidate gets FDA Breakthrough Therapy designation https://seekingalpha.com/news/3268305-glycomimetics-drug-candidate-gets-fda-breakthrough-therapy-designation?source=tweet\" data-url=\"https://seekingalpha.com/news/3268305-glycomimetics-drug-candidate-gets-fda-breakthrough-therapy-designation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268304\" data-ts=\"1495059583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIRI\" target=\"_blank\">SIRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268304-pandora-jumps-on-latest-report-of-sirius-xm-buyout-talks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pandora jumps on latest report of Sirius XM buyout talks</a></h4><ul>     <li>Pandora Media (<a href=\"http://seekingalpha.com/symbol/P\" target=\"_blank\">P</a> <font color='red'>-4.5%</font>) is <font color='green'>up 7.5%</font> after hours on the latest report that Sirius XM (NASDAQ:<a href='https://seekingalpha.com/symbol/SIRI' title='Sirius XM Holdings Inc.'>SIRI</a>) is in <a href=\"https://nypost.com/2017/05/17/siriusxm-in-discussions-to-acquire-struggling-pandora/\" target=\"_blank\">talks for a takeover</a> of the struggling streamer.</li>     <li>Sirius XM is in \"active discussions\" with Pandora's banks about a bid, the <i>New York Post</i> says.</li>     <li>One of its \"optimistic\" sources puts a bid as high as $12-$13 a share, a price \"immediately shot down\" by familiar sources. Pandora closed down to $8.93 today and is quoting at $9.60 after hours.</li>   <li>In March, after on-again, off-again rumors of a SIRI/P linkup, Pandora chief Tim Westergren said the <a href=\"https://seekingalpha.com/news/3250695-pandora-ceo-companys-sale-headed-profit-year\" target=\"_blank\">company wasn't for sale</a> and would get to profitability this year.</li>    <li><a href=\"https://seekingalpha.com/news/search?query=sirius+pandora\" target=\"_blank\">Past coverage</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3268304\" data-linked=\"Pandora jumps on latest report of Sirius XM buyout talks\" data-tweet=\"$SIRI $SIRI $P - Pandora jumps on latest report of Sirius XM buyout talks https://seekingalpha.com/news/3268304-pandora-jumps-on-latest-report-of-sirius-xm-buyout-talks?source=tweet\" data-url=\"https://seekingalpha.com/news/3268304-pandora-jumps-on-latest-report-of-sirius-xm-buyout-talks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>139&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268294\" data-ts=\"1495056908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268294-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='green'>+36.1%</font>. <a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='green'>+6.8%</font>. <a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen'>AKAO</a> <font color='green'>+6.4%</font>. <a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a> <font color='green'>+5.6%</font>. <a href='https://seekingalpha.com/symbol/SSW' title='Seaspan Corporation'>SSW</a> <font color='green'>+4.7%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/SMRT' title='Stein Mart, Inc.'>SMRT</a> <font color='red'>-21.7%</font>. <a href='https://seekingalpha.com/symbol/ELGX' title='Endologix Inc'>ELGX</a> <font color='red'>-18.2%</font>. <a href='https://seekingalpha.com/symbol/NLNK' title='NewLink Genetics Corporation'>NLNK</a> <font color='red'>-16.1%</font>. <a href='https://seekingalpha.com/symbol/CSCO' title='Cisco Systems, Inc.'>CSCO</a> <font color='red'>-8.1%</font>. <a href='https://seekingalpha.com/symbol/GMED' title='Globus Medical'>GMED</a> <font color='red'>-7.1%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268294\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$GLYC $LB $AKAO - After Hours Gainers / Losers https://seekingalpha.com/news/3268294-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3268294-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268275\" data-ts=\"1495054794\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELGX\" target=\"_blank\">ELGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268275-endologix-to-run-new-confirmatory-study-to-support-u-s-marketing-application-for-nellix-evas\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Endologix to run new confirmatory study to support U.S. marketing application for Nellix EVAS; FDA OK expected in 2020; shares down 3% after hours</a></h4><ul><li>Based on FDA feedback, Endologix (NASDAQ:<a href='https://seekingalpha.com/symbol/ELGX' title='Endologix Inc'>ELGX</a>) will <a href=\"https://seekingalpha.com/pr/16836729-endologix-provides-update-nellix-endovascular-aneurysm-sealing-system-u-s-regulatory-status\" target=\"_blank\">conduct a new confirmatory study</a> on its Nellix Endovascular Aneurysm Sealing System &#40;EVAS&#41;. The new study will utilize previously updated instructions for use and the Gen2 device design, currently marketed in Europe and other international markets.</li><li>The company expects enrollment to commence in Q4. If all goes well, regulatory approval should happen in 2020.</li><li>Shares are down&nbsp;<font color='red'>3%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268275\" data-linked=\"Endologix to run new confirmatory study to support U.S. marketing application for Nellix EVAS; FDA OK expected in 2020; shares down 3% after hours\" data-tweet=\"$ELGX - Endologix to run new confirmatory study to support U.S. marketing application for Nellix EVAS; FDA OK expected in 2020; shares down 3% after hours https://seekingalpha.com/news/3268275-endologix-to-run-new-confirmatory-study-to-support-u-s-marketing-application-for-nellix-evas?source=tweet\" data-url=\"https://seekingalpha.com/news/3268275-endologix-to-run-new-confirmatory-study-to-support-u-s-marketing-application-for-nellix-evas\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268274\" data-ts=\"1495054679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268274-l-brands-higher-after-boosting-profit-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">L Brands higher after boosting profit guidance</a></h4><ul>     <li>L Brands (NYSE:<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a>) reports comparable sales fell 9% in Q1, driven lower by a 14% drop for the Victoria's Secret business.</li>     <li>The company boosts 2017 full-year EPS to $3.10 to $3.40, from $3.05 to $3.35 prior. Q2 EPS of&nbsp;$0.40 and $0.45 is expected vs. $0.46 consensus.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3268259-l-brands-beats-0_04-revenue-line\" target=\"_blank\">L Brands beats by $0.04,  revenue in-line</a> (May 17)</li><li>L Brands&nbsp;<font color='green'>+8.0%</font>&nbsp;AH to $52.25.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268274\" data-linked=\"L Brands higher after boosting profit guidance\" data-tweet=\"$LB - L Brands higher after boosting profit guidance https://seekingalpha.com/news/3268274-l-brands-higher-after-boosting-profit-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3268274-l-brands-higher-after-boosting-profit-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268272\" data-ts=\"1495054225\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268272-ascena-plunges-32-after-slashing-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena plunges 32% after slashing outlook</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16836638-ascena-retail-group-provides-fiscal-q3-full-year-2017-guidance-update-identifies-significant\" target=\"_blank\">The company sees</a> Q3 adjusted EPS of $0.04-$0.06 vs. $0.07-$0.12 previously. Street estimates are for $0.09. Comparable sales are seen down 8%.</li><li>Full-year adjusted EPS is now guided to $0.10-$0.15 from $0.37-$0.42 previously, and Street estimates of $0.38. Comparable sales are seen down 6%-7%.</li><li>CEO David Jaffe: \"The specialty retail sector is in a period of unprecedented secular change that is disruptive to traditional business models, and we believe operating conditions in our sector are likely to remain challenging for the next 12 to 24 months.\"</li><li><a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a>&nbsp;<font color='red'>-32.6%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3268272\" data-linked=\"Ascena plunges 32% after slashing outlook\" data-tweet=\"$ASNA - Ascena plunges 32% after slashing outlook https://seekingalpha.com/news/3268272-ascena-plunges-32-after-slashing-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3268272-ascena-plunges-32-after-slashing-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268261\" data-ts=\"1495053368\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268261-fda-oks-expanded-use-of-vertexs-cf-med-kalydeco-shares-ahead-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs expanded use of Vertex&#39;s CF med Kalydeco; shares ahead 1% after hours</a></h4><ul><li>The FDA has <a href=\"https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm559212.htm\" target=\"_blank\">approved</a> the use of Vertex Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) <a href=\"http://www.kalydeco.com/\" target=\"_blank\">Kalydeco</a> (ivacaftor) for the treatment of cystic fibrosis patients with 33 genetic mutations, up from 10 mutations.</li><li>The agency based its approval, in part, on laboratory test results. It used these data with results from earlier clinical trials as the basis for its decision, providing a pathway for adding additional CF-related mutations.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268261\" data-linked=\"FDA OKs expanded use of Vertex&#39;s CF med Kalydeco; shares ahead 1% after hours\" data-tweet=\"$VRTX - FDA OKs expanded use of Vertex&#39;s CF med Kalydeco; shares ahead 1% after hours https://seekingalpha.com/news/3268261-fda-oks-expanded-use-of-vertexs-cf-med-kalydeco-shares-ahead-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3268261-fda-oks-expanded-use-of-vertexs-cf-med-kalydeco-shares-ahead-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268259\" data-ts=\"1495053255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268259-l-brands-beats-0_04-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">L Brands beats by $0.04,  revenue in-line</a></h4><ul><li>L Brands (NYSE:<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a>): Q1 EPS of $0.33 <font color='green'>beats by $0.04</font>.</li><li>Revenue of $2.44B (-6.5% Y/Y) in-line.</li><li>Shares <font color='green'>+5%</font>.</li><li><a href='https://seekingalpha.com/pr/16836705-l-brands-reports-first-quarter-earnings'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3268259\" data-linked=\"L Brands beats by $0.04,  revenue in-line\" data-tweet=\"$LB - L Brands beats by $0.04, revenue in-line https://seekingalpha.com/news/3268259-l-brands-beats-0_04-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3268259-l-brands-beats-0_04-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268243\" data-ts=\"1495052210\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CSCO\" target=\"_blank\">CSCO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268243-ciscominus-4_8-current-quarter-guidance-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cisco -4.8% as current-quarter guidance disappoints</a></h4><ul>   <li>Cisco Systems (<a href=\"http://seekingalpha.com/symbol/CSCO\" target=\"_blank\">CSCO</a> <font color='red'>-1.4%</font>) has <font color='red'>fallen another 4.8%</font> in heavy after-hours volume after posting <a href=\"https://seekingalpha.com/news/3268233-cisco-beats-0_02-beats-revenue\" target=\"_blank\">fiscal Q3 earnings</a> that beat expectations but held guidance for a Q4 revenue drop of 4-6%.</li>    <li>It's expecting non-GAAP EPS of $0.60-$0.62 in Q4, vs. consensus for $0.62. And the revenue forecast comes to $11.88B-$12.13B, well below consensus for $12.53B.</li>    <li>For the Q3 report, revenues overall were down 0.5%, and non-GAAP net income rose 5% to $3B. The quarter had 13 weeks vs. 14 weeks a year ago.</li>    <li>Some 31% of revenue was from recurring offers, up from 29% a year ago. Product performance was led by Wireless (up 13%) and Security (up 9%), while Switching revenue gained 2%.</li>    <li>Revenue breakout: Product, $8.885B (up 0.1%); Service, $3.055B (down 2.2%).</li>    <li>\"We executed well in Q3, delivering $11.9 billion in total revenue, while driving solid profitability and cash generation as we deliver on our strategic priorities,\" says CFO Kelly Kramer.</li><li>The company's extending a previous restructuring with 1,100 more jobs cuts, and a corresponding $150M pretax charge.</li>    <li><a href=\"http://investor.cisco.com\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16836617-cisco-reports-third-quarter-earnings\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3268243\" data-linked=\"Cisco -4.8% as current-quarter guidance disappoints\" data-tweet=\"$CSCO - Cisco -4.8% as current-quarter guidance disappoints https://seekingalpha.com/news/3268243-ciscominus-4_8-current-quarter-guidance-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3268243-ciscominus-4_8-current-quarter-guidance-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268224\" data-ts=\"1495051174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRTX\" target=\"_blank\">MRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268224-mirati-perks-up-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mirati perks up 9%</a></h4><ul><li>Thinly traded nano cap Mirati Therapeutics (<a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a> <font color='green'>+9%</font>) bucks the market's sour mood on double normal volume. No particular news accounts for the move although investors may be taking positions ahead of ASCO's abstract drop this afternoon.</li><li>The company's lead candidates are Phase 2-stage <a href=\"http://www.mirati.com/programs/mgcd265/\" target=\"_blank\">glesatinib </a>for non-small cell lung cancer and Phase 1b-stage <a href=\"http://www.mirati.com/go/mgcd516/\" target=\"_blank\">sitravatinib </a>for solid tumors.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268224\" data-linked=\"Mirati perks up 9%\" data-tweet=\"$MRTX - Mirati perks up 9% https://seekingalpha.com/news/3268224-mirati-perks-up-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3268224-mirati-perks-up-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268223\" data-ts=\"1495051042\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INSW\" target=\"_blank\">INSW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268223-intl-seaways-euronav-win-fso-contract-seen-generating-360m-ebitda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Int&#39;l Seaways, Euronav win FSO contract seen generating $360M EBITDA</a></h4><ul>     <li>International Seaways (<a href='https://seekingalpha.com/symbol/INSW' title='International Seaways'>INSW</a> <font color='green'>+2.4%</font>) pushes higher on news that its 50-50 joint venture with Euronav (<a href='https://seekingalpha.com/symbol/EURN' title='Euronav NV'>EURN</a> <font color='green'>+0.6%</font>) received a <a href=\"https://seekingalpha.com/pr/16835429-international-seaways-announces-execution-five-year-contracts-fso-joint-venture\" target=\"_blank\">five-year contract extension</a> from North Oil Co. for the <em>FSO Africa</em> and <em>FSO Asia</em> floating storage platforms.</li><li>North Oil is the future operator of the Al Shaheen oil field offshore Qatar, and the two FSOs have been serving the field       for Maersk Oil since 2010.</li><li>INSW says the new contracts will generate more than $360M of EBITDA for the JV over the five year period.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268223\" data-linked=\"Int&#39;l Seaways, Euronav win FSO contract seen generating $360M EBITDA\" data-tweet=\"$INSW $INSW $EURN - Int&#39;l Seaways, Euronav win FSO contract seen generating $360M EBITDA https://seekingalpha.com/news/3268223-intl-seaways-euronav-win-fso-contract-seen-generating-360m-ebitda?source=tweet\" data-url=\"https://seekingalpha.com/news/3268223-intl-seaways-euronav-win-fso-contract-seen-generating-360m-ebitda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268221\" data-ts=\"1495050844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDP\" target=\"_blank\">MDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268221-time-inc-opening-two-new-southern-living-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Time Inc. opening two new Southern Living stores</a></h4><ul>   <li>Time Inc. (<a href=\"http://seekingalpha.com/symbol/TIME\" target=\"_blank\">TIME</a> <font color='red'>-2.8%</font>) is opening <a href=\"https://seekingalpha.com/pr/16836280-time-inc-s-southern-living-launches-two-new-branded-retail-stores\" target=\"_blank\">two more retail stores</a> based on its Southern Living magazine brand.</li>    <li>The new stores, in Destin, Fla., and Huntsville, Ala., will join an existing Southern Living store in Myrtle Beach, S.C.</li>    <li>Branded books will be on sale along with items from local artists and producers, and the stores will host book signings and visits from artists along with food and tea tastings.</li>    <li>The new stores will open in late May.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268221\" data-linked=\"Time Inc. opening two new Southern Living stores\" data-tweet=\"$MDP - Time Inc. opening two new Southern Living stores https://seekingalpha.com/news/3268221-time-inc-opening-two-new-southern-living-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3268221-time-inc-opening-two-new-southern-living-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268218\" data-ts=\"1495049663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PULM\" target=\"_blank\">PULM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268218-pulmatrix-up-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pulmatrix up 21%</a></h4><ul><li>Pulmatrix (<a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+21%</font>) is showing some life as the session draws to a close. Shares are up on more than double normal volume on no particular news. Since rallying almost eight-fold at the beginning of the year, shares have been in a downtrend.</li><li>The company's most advanced product candidate is Phase 2-stage PUR0200 for the treatment of COPD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268218\" data-linked=\"Pulmatrix up 21%\" data-tweet=\"$PULM - Pulmatrix up 21% https://seekingalpha.com/news/3268218-pulmatrix-up-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3268218-pulmatrix-up-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268216\" data-ts=\"1495049472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIN\" target=\"_blank\">WIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268216-windstreamplus-6-unitiplus-3-on-raymond-james-bullishness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Windstream +6%, Uniti +3% on Raymond James bullishness</a></h4><ul>   <li>Windstream Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a>) is <font color='green'>up 6%</font> after a wholesale two-notch upgrade to Outperform at Raymond James.</li>    <li>The firm says a sell-off this year (WIN is <font color='red'>down 37.2%</font> YTD) is overdone, and acquisitions like Broadview are raising outlook for free cash flow.</li>    <li>Analyst Frank Louthan IV also likes the company's spin-off Uniti Group (<a href=\"http://seekingalpha.com/symbol/UNIT\" target=\"_blank\">UNIT</a> <font color='green'>+3%</font>) -- formerly CS&amp;L -- ranking it a Strong Buy.</li>    <li>He's set a price target for <a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a> of $5.25 (implying 14.4% upside from today's raised price) but $8 isn't out of the question if the company can reverse revenue trends, he says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268216\" data-linked=\"Windstream +6%, Uniti +3% on Raymond James bullishness\" data-tweet=\"$WIN $WINMQ $UNIT - Windstream +6%, Uniti +3% on Raymond James bullishness https://seekingalpha.com/news/3268216-windstreamplus-6-unitiplus-3-on-raymond-james-bullishness?source=tweet\" data-url=\"https://seekingalpha.com/news/3268216-windstreamplus-6-unitiplus-3-on-raymond-james-bullishness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268214\" data-ts=\"1495048832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MS\" target=\"_blank\">MS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268214-traders-still-expecting-june-rate-hike-though-odds-slimmed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Traders still expecting June rate hike (though odds have slimmed)</a></h4><ul><li>With the 10-year Treasury yield down a full 11 basis points to roughly its weakest level since shortly after the November election, and financial stocks plunging, it's <a href=\"http://www.cmegroup.com/trading/interest-rates/stir/30-day-federal-fund.html\" target=\"_blank\">worth a check of short-term rate futures</a> to see if a June rate hike (as more or less promised by the Fed) continues to be priced in.</li><li>Turns out Fed Fund futures are sharply higher today (i.e. pricing in less of a chance for hikes), with the July contract up 3.5 basis points to price in a 60% chance of a move in June.</li><li>Slowing inflation could give the FOMC the excuse it needs to take a pause, but the jobs market continues to rip and unemployment to fall. Among those whose hopes for continued higher rates (and eased regulations) are currently dashed: Morgan Stanley (<a href='https://seekingalpha.com/symbol/MS' title='Morgan Stanley'>MS</a> <font color='red'>-5.8%</font>), Bank of America (<a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a> <font color='red'>-5.6%</font>), Schwab (<a href='https://seekingalpha.com/symbol/SCHW' title='The Charles Schwab Corporation'>SCHW</a> <font color='red'>-6.2%</font>), MetLife (<a href='https://seekingalpha.com/symbol/MET' title='MetLife, Inc.'>MET</a> <font color='red'>-3.6%</font>), Regions Financial (<a href='https://seekingalpha.com/symbol/RF' title='Regions Financial Corporation'>RF</a> <font color='red'>-3.1%</font>), KeyCorp (<a href='https://seekingalpha.com/symbol/KEY' title='KeyCorp'>KEY</a> <font color='red'>-4.3%</font>), PNC Financial (<a href='https://seekingalpha.com/symbol/PNC' title='PNC Financial Services Group, Inc.'>PNC</a> <font color='red'>-3.8%</font>), Comerica (<a href='https://seekingalpha.com/symbol/CMA' title='Comerica Inc.'>CMA</a> <font color='red'>-5.1%</font>), Huntington Bancshares (<a href='https://seekingalpha.com/symbol/HBAN' title='Huntington Bancshares Incorporated'>HBAN</a> <font color='red'>-5.1%</font>), State Street (<a href='https://seekingalpha.com/symbol/STT' title='State Street Corporation'>STT</a> <font color='red'>-3.5%</font>), Lincoln National (<a href='https://seekingalpha.com/symbol/LNC' title='Lincoln National Corporation'>LNC</a> <font color='red'>-5%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/XLF' title='Financial Select Sector SPDR ETF'>XLF</a>, <a href='https://seekingalpha.com/symbol/FAS' title='Direxion Daily Financial Bull 3x Shares ETF'>FAS</a>, <a href='https://seekingalpha.com/symbol/FAZ' title='Direxion Daily Financial Bear 3x Shares ETF'>FAZ</a>, <a href='https://seekingalpha.com/symbol/UYG' title='ProShares Ultra Financials ETF'>UYG</a>, <a href='https://seekingalpha.com/symbol/VFH' title='Vanguard Financials ETF'>VFH</a>, <a href='https://seekingalpha.com/symbol/IYF' title='iShares U.S. Financials ETF'>IYF</a>, <a href='https://seekingalpha.com/symbol/BTO' title='John Hancock Financial Opportunity Fund'>BTO</a>, <a href='https://seekingalpha.com/symbol/IYG' title='iShares U.S. Financial Services ETF'>IYG</a>, <a href='https://seekingalpha.com/symbol/FNCL' title='Fidelity MSCI Financials Index ETF'>FNCL</a>, <a href='https://seekingalpha.com/symbol/SEF' title='ProShares Short Financials ETF'>SEF</a>, <a href='https://seekingalpha.com/symbol/FXO' title='First Trust Financials AlphaDEX ETF'>FXO</a>, <a href='https://seekingalpha.com/symbol/RYF' title='Invesco S&P Equal Weight Financial ETF'>RYF</a>, <a href='https://seekingalpha.com/symbol/FINU' title='ProShares UltraPro Financials ETF'>FINU</a>, <a href='https://seekingalpha.com/symbol/RWW' title='Oppenheimer Financials Sector Revenue ETF'>RWW</a>, <a href='https://seekingalpha.com/symbol/XLFS' title='Financial Services Select Sector SPDR ETF'>XLFS</a>, <a href='https://seekingalpha.com/symbol/FINZ' title='ProShares UltraPro Short Financials ETF'>FINZ</a>, <a href='https://seekingalpha.com/symbol/JHMF' title='John Hancock Multifactor Financials ETF'>JHMF</a>, <a href='https://seekingalpha.com/symbol/FAZZ' title='Direxion Daily Financial Bear 1x Shares ETF'>FAZZ</a>, <a href='https://seekingalpha.com/symbol/FNCF' title='iShares Edge MSCI Multifactor Financials ETF'>FNCF</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3268214\" data-linked=\"Traders still expecting June rate hike (though odds have slimmed)\" data-tweet=\"$MS $MS $BAC - Traders still expecting June rate hike (though odds have slimmed) https://seekingalpha.com/news/3268214-traders-still-expecting-june-rate-hike-though-odds-slimmed?source=tweet\" data-url=\"https://seekingalpha.com/news/3268214-traders-still-expecting-june-rate-hike-though-odds-slimmed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268213\" data-ts=\"1495048732\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FMSA\" target=\"_blank\">FMSA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268213-frac-sand-suppliers-smacked-fairmount-santrol-provides-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frac sand suppliers smacked as Fairmount Santrol provides outlook</a></h4><ul>     <li>Fairmount Santrol (<a href='https://seekingalpha.com/symbol/FMSA' title='Fairmount Santrol, Inc.'>FMSA</a> <font color='red'>-5%</font>) says in an <a href=\"https://seekingalpha.com/filing/3553609\" target=\"_blank\">investor presentation</a> that it expects Q2 volumes of 3.2M-3.5M tons, with raw frac sand prices rising $7-$9/ton on average during the quarter and extending those gains during Q3.</li><li>FMSA says proppant solutions volumes should be driven by continued strong  demand and additional capacity coming online at Brewer and Maiden Rock  locations.</li><li>Frac sand suppliers are hit hard amid broader market losses today: <a href='https://seekingalpha.com/symbol/SLCA' title='U.S. Silica'>SLCA</a> <font color='red'>-4.2%</font>, <a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='red'>-2.6%</font>, <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-5.1%</font>, <a href='https://seekingalpha.com/symbol/EMES' title='Emerge Energy Services LP'>EMES</a> <font color='red'>-6.7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268213\" data-linked=\"Frac sand suppliers smacked as Fairmount Santrol provides outlook\" data-tweet=\"$FMSA $FMSA $SLCA - Frac sand suppliers smacked as Fairmount Santrol provides outlook https://seekingalpha.com/news/3268213-frac-sand-suppliers-smacked-fairmount-santrol-provides-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3268213-frac-sand-suppliers-smacked-fairmount-santrol-provides-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268212\" data-ts=\"1495048717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268212-reports-facebook-facing-fine-over-misleading-whatsapp-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Reports: Facebook facing fine over misleading WhatsApp review</a></h4><ul>    <li>Facebook (<a href=\"http://seekingalpha.com/symbol/FB\" target=\"_blank\">FB</a> <font color='red'>-2.6%</font>) is nearing a penalty from Europe tied to allegations that the company provided <a href=\"http://www.reuters.com/article/us-eu-facebook-antitrust-idUSKCN18D2HL\" target=\"_blank\">misleading data around its WhatsApp acquisition</a>, according to media reports.</li>    <li>The European Commission has been probing the 2014 deal for the past six months, and a potentially stiff fine would send a message to other companies in the same situation. The Commission is empowered to fine a company as much as 1% of global turnover (for Facebook, a fine of up to $276M).</li>    <li>During the deal's review, Facebook told the EC that it was unable to reliably match user accounts at the two companies, but the EC found that it was in fact technically possible.</li>    <li>Europe's Competition Commissioner Margrethe Vestager has warned against companies providing misleading information as part of merger reviews.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268212\" data-linked=\"Reports: Facebook facing fine over misleading WhatsApp review\" data-tweet=\"$FB - Reports: Facebook facing fine over misleading WhatsApp review https://seekingalpha.com/news/3268212-reports-facebook-facing-fine-over-misleading-whatsapp-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3268212-reports-facebook-facing-fine-over-misleading-whatsapp-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268210\" data-ts=\"1495048231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/S\" target=\"_blank\">S</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268210-sprint-deploying-iot-friendly-standard-julys-end\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sprint deploying IoT-friendly standard by July&#39;s end</a></h4><ul>   <li>Sprint (NYSE:<a href='https://seekingalpha.com/symbol/S' title='Sprint Corporation'>S</a>) has said that it will deploy LTE Cat 1 across its network by the end of July, spreading a network technology <a href=\"http://www.bizjournals.com/kansascity/news/2017/05/17/sprint-lte-cat-1-technology-implementation.html?ana=yahoo&amp;yptr=yahoo\" target=\"_blank\">optimized for the Internet of Things</a>.</li>    <li>The tech -- which actually limits download/upload speeds to 10 Mbps/5 Mbps -- will reduce cost and extend battery life for connected devices.</li>    <li>It's targeting industrial IoT applications, vending machines and vehicle technologies.</li>    <li>The company will follow that deployment with two others in 2018: LTE Cat M1 and Cat MB1, extending usage for low-power applications.</li>    <li>Along with a sliding market today, shares are <font color='red'>7.2% lower</font>, hitting their lowest point since November.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268210\" data-linked=\"Sprint deploying IoT-friendly standard by July&#39;s end\" data-tweet=\"$S - Sprint deploying IoT-friendly standard by July&#39;s end https://seekingalpha.com/news/3268210-sprint-deploying-iot-friendly-standard-julys-end?source=tweet\" data-url=\"https://seekingalpha.com/news/3268210-sprint-deploying-iot-friendly-standard-julys-end\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268207\" data-ts=\"1495047672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268207-stocks-session-lows-nasdaq-tumbles-2-bond-prices-soar\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks at session lows; Nasdaq tumbles more than 2%; bond prices soar</a></h4><ul><li>&ldquo;This isn&rsquo;t about who is right or wrong [in Comey affair],\" <a href=\"http://www.marketwatch.com/story/us-stock-futures-slide-as-concerns-over-trump-grow-2017-05-17\" target=\"_blank\">says fixed-income analyst Kevin Giddis</a>. \"It is about a concern that a number of things could derail the future of economic growth that were not present a month ago.\"</li><li>The Nasdaq leads to the downside with a&nbsp;<font color='red'>2.2% decline</font>. The S&amp;P 500 and DJIA are each&nbsp;<font color='red'>off about 1.5%</font>.</li><li>Within sectors, pretty much every reason for piling into financials since the election no longer holds. The XLF is&nbsp;<font color='red'>down 3.2%</font>, with the KBW Bank ETF&nbsp;<font color='red'>down 4.15%</font>. Only the income favorite utility sector is in the green on the session.</li><li>The 10-year Treasury yield is down a whopping 11 basis points to 2.127%, and gold is&nbsp;<font color='green'>up 1.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268207\" data-linked=\"Stocks at session lows; Nasdaq tumbles more than 2%; bond prices soar\" data-tweet=\"Stocks at session lows; Nasdaq tumbles more than 2%; bond prices soar https://seekingalpha.com/news/3268207-stocks-session-lows-nasdaq-tumbles-2-bond-prices-soar?source=tweet\" data-url=\"https://seekingalpha.com/news/3268207-stocks-session-lows-nasdaq-tumbles-2-bond-prices-soar\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268204\" data-ts=\"1495047629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268204-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CYOU' title='Changyou.com Limited'>CYOU</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PLAB' title='Photronics, Inc.'>PLAB</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268204\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$CYOU $HMNY $WINMQ - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3268204-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3268204-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268203\" data-ts=\"1495047511\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268203-puma-bio-up-15-on-body-language-of-ceo-investor-conference\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Puma Bio up 15% on &quot;body language&quot; of CEO at investor conference</a></h4><ul><li>In one of the more interesting reasons attributed to a stock's move, buying has picked up Puma Biotechnology (<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+14.7%</font>) on the basis of \"balanced/positive\" body language by CEO Alan Auerbach during one-on-ones at the Bank of America investor conference.</li><li>The company's lead product candidate is neratinib, currently under review in the U.S. and EU for HER2-positive breast cancer.</li><li>RBC's Matthew Eckler issued a <a href=\"https://finance.yahoo.com/m/cf5d10fd-4690-33bb-a5c6-2a5974fafb67/ss_puma-leaps-on-report-its.html\" target=\"_blank\">bullish report</a> saying neratinib should stand up to Roche's combination treatment and&nbsp;\"unnamed experts\" who say it could have a place as adjunctive treatment.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268203\" data-linked=\"Puma Bio up 15% on &quot;body language&quot; of CEO at investor conference\" data-tweet=\"$PBYI - Puma Bio up 15% on &quot;body language&quot; of CEO at investor conference https://seekingalpha.com/news/3268203-puma-bio-up-15-on-body-language-of-ceo-investor-conference?source=tweet\" data-url=\"https://seekingalpha.com/news/3268203-puma-bio-up-15-on-body-language-of-ceo-investor-conference\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268201\" data-ts=\"1495047102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLUG\" target=\"_blank\">PLUG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268201-plug-powerminus-15-despite-ceos-rebuttal-of-roth-capitals-sell-case\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plug Power -15% despite CEO&#39;s rebuttal of Roth Capital&#39;s Sell case</a></h4><ul>     <li>Plug Power (<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='red'>-15%</font>) CEO Andy Marsh <a href=\"http://www.plugpower.com/2017/05/reiterating-guidance-from-andy-marsh/\" target=\"_blank\">refutes \"misinformation\"</a> he says was discussed in a negative note earlier today from Roth Capital analyst Craig Irwin, who <a href=\"https://seekingalpha.com/news/3268143-plug-minus-7-percent-downgrade-roth\" target=\"_blank\">downgraded shares to Sell</a> from Neutral, and repeats FY 2017 guidance.</li>     <li>PLUG's \"shipping plans for Wal-Mart have not changed,\" Irwin says, the \"strike price and number of Amazon warrants remains the same as announced on April 5,\" and the \"recent announcements with major customers have increased new customer interest in our products, across the board.\"</li>     <li>The CEO also repeats FY 2017 guidance for revenues of $130M, GenDrive shipments of 5,600; gross margin of 8%-12%, and bookings of  $325M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268201\" data-linked=\"Plug Power -15% despite CEO&#39;s rebuttal of Roth Capital&#39;s Sell case\" data-tweet=\"$PLUG - Plug Power -15% despite CEO&#39;s rebuttal of Roth Capital&#39;s Sell case https://seekingalpha.com/news/3268201-plug-powerminus-15-despite-ceos-rebuttal-of-roth-capitals-sell-case?source=tweet\" data-url=\"https://seekingalpha.com/news/3268201-plug-powerminus-15-despite-ceos-rebuttal-of-roth-capitals-sell-case\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268200\" data-ts=\"1495046678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/Z\" target=\"_blank\">Z</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268200-zillowminus-6_3-susquehanna-warns-of-co-marketing-regulatory-threat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zillow -6.3%; Susquehanna warns of co-marketing regulatory threat</a></h4><ul>   <li>A probe into co-marketing programs at Zillow (<a href=\"http://seekingalpha.com/symbol/Z\" target=\"_blank\">Z</a> <font color='red'>-6.3%</font>) by the Consumer Financial Protection Bureau could threaten that revenue stream, Susquehanna says.</li>    <li>The firm's expecting some form of fine (likely relatively low, in tens of millions of dollars) and other restrictions, up to revamping or even discontinuing co-marketing.</li>    <li>That means a \"significant\" amount of EBITDA is at risk, says analyst Thomas Claps.</li>    <li>Formal action may be coming soon since the CFPB issued a \"Notice and Opportunity to Respond and Advise\" letter.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268200\" data-linked=\"Zillow -6.3%; Susquehanna warns of co-marketing regulatory threat\" data-tweet=\"$Z - Zillow -6.3%; Susquehanna warns of co-marketing regulatory threat https://seekingalpha.com/news/3268200-zillowminus-6_3-susquehanna-warns-of-co-marketing-regulatory-threat?source=tweet\" data-url=\"https://seekingalpha.com/news/3268200-zillowminus-6_3-susquehanna-warns-of-co-marketing-regulatory-threat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268197\" data-ts=\"1495046296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPN\" target=\"_blank\">CPN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268197-calpineplus-5-m-speculation-ramps-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Calpine +5% as M&amp;A speculation ramps up</a></h4><ul>     <li>Calpine (<a href='https://seekingalpha.com/symbol/CPN' title='Calpine Corporation'>CPN</a> <font color='green'>+4.8%</font>) shares have spiked higher over the past hour on reports that the company's sale auction has <a href=\"https://twitter.com/OpenOutcrier/status/864899871698038789\" target=\"_blank\">moved into the second round</a>, with five potential suitors involved including P-E firms Blackstone (<a href='https://seekingalpha.com/symbol/BK' title='The Bank of New York Mellon Corporation'>BK</a> <font color='red'>-2%</font>) and Carlyle (<a href='https://seekingalpha.com/symbol/CG' title='The Carlyle Group'>CG</a> <font color='red'>-3.5%</font>).</li>     <li>CPN first surged higher <a href=\"https://seekingalpha.com/news/3265995-calpine-plus-14-percent-wsj-says-exploring-sale\" target=\"_blank\">a week ago</a> after the <em>WSJ</em> reported the company was working with Lazard to sound out potential buyers.</li>     <li>Analysts have been divided on takeover prospects: Citi's Praful Mehta says CPN could be <a href=\"http://thefly.com/thestreet/realmoney/index.php/CPNid2550844/CPN-Calpine-takeout-could-happen-at--per-share-says-Citi\" target=\"_blank\">worth $14-$15 in a buyout</a> and that a sale could generate good interest from private equity, while Tudor Pickering thinks a <a href=\"http://thefly.com/thestreet/realmoney/index.php/CPNid2550582/CPN-Calpine-takeout-unlikely-says-Tudor-Pickering\" target=\"_blank\">takeout is unlikely</a>, saying the company is too big for one acquirer and a large consortium would be needed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268197\" data-linked=\"Calpine +5% as M&amp;A speculation ramps up\" data-tweet=\"$CPN $CPN $BK - Calpine +5% as M&amp;A speculation ramps up https://seekingalpha.com/news/3268197-calpineplus-5-m-speculation-ramps-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3268197-calpineplus-5-m-speculation-ramps-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268195\" data-ts=\"1495045375\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HD\" target=\"_blank\">HD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268195-trends-still-strong-for-home-depot\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trends still strong for Home Depot</a></h4><ul>     <li>Home Depot (<a href='https://seekingalpha.com/symbol/HD' title='Home Depot, Inc.'>HD</a> <font color='red'>-1%</font>) is off of its all-time high struck yesterday, but analysts are still weighing on <a href=\"https://www.thestreet.com/story/14138143/1/one-of-home-depot-s-most-powerful-executives-just-gave-a-master-class-on-how-to-be-a-retailer.html\" target=\"_blank\">positively</a> on the retailer due its positioning as a relatively Amazon-proof chain in an area of vibrant consumer spending.</li>     <li>\"Home improvement spending still remains healthier than most areas in retail,\" notes Jefferies analyst Dan Binder.</li>     <li>\"The industry is lapping the toughest quarterly comparison of the year, led by a strong February last year. However, trends remain strong as quarter to date building materials, hardware and garden supply sales (according to government figures) have grown 6.4% year over year while lapping a 10.1% growth over the same time period last year,\" he adds.</li>     <li>More to come? Take a look at what Home Depot CFO Carol Tome told TheStreet.com on the notion of trimming its store base.</li>     <li>Tome:&nbsp;\"All of our stores are cash flow positive. The net present value of operating each of our stores is greater than the net present value of closing the store. So I don't have a list of stores that I am worried about.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268195\" data-linked=\"Trends still strong for Home Depot\" data-tweet=\"$HD - Trends still strong for Home Depot https://seekingalpha.com/news/3268195-trends-still-strong-for-home-depot?source=tweet\" data-url=\"https://seekingalpha.com/news/3268195-trends-still-strong-for-home-depot\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268193\" data-ts=\"1495044058\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268193-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PACD' title='Pacific Drilling SA'>PACD</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='red'>-12%</font>. PGH <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corp'>LTBR</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/HSC' title='Harsco Corporation'>HSC</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268193\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$PACD $AU $DELT-OLD - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3268193-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3268193-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268190\" data-ts=\"1495042898\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KAR\" target=\"_blank\">KAR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268190-carsarrive-network-acquires-dependable-auto-shippers-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CarsArrive network acquires Dependable Auto Shippers business</a></h4><ul><li>KAR Auction Services (<a href='https://seekingalpha.com/symbol/KAR' title='KAR Auction Services'>KAR</a> <font color='red'>-0.6%</font>) announced that its CarsArrive Network subsidiary has acquired the vehicle transportation business of Dependable Auto Shippers.</li><li>The addition of&nbsp;Dependable Auto Shippers&nbsp;will extend CarsArrive&rsquo;s transportation and logistics solutions into the growing consumer market segment.</li>   <li>&ldquo;CarsArrive has developed a leading portfolio of products and services that help dealers, wholesalers, fleet managers and other commercial customers ship their vehicles safely and efficiently,&rdquo; said Michael Briggs, president and CEO of CarsArrive and Recovery Database Network, Inc.</li>    <li>&ldquo;If there&rsquo;s a vehicle to be moved in any channel for any customer, CarsArrive wants to be there to move it,&rdquo; said Briggs. &ldquo;Consumer-centricity is the next phase in our evolution, and we&rsquo;ll bring the strength and confidence of the entire KAR platform to help us deliver value, convenience and exceptional service.&rdquo;</li>    <li><a href=\"https://seekingalpha.com/pr/16836431-carsarrive-network-acquires-dependable-auto-shippers-business\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3268190\" data-linked=\"CarsArrive network acquires Dependable Auto Shippers business\" data-tweet=\"$KAR - CarsArrive network acquires Dependable Auto Shippers business https://seekingalpha.com/news/3268190-carsarrive-network-acquires-dependable-auto-shippers-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3268190-carsarrive-network-acquires-dependable-auto-shippers-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268189\" data-ts=\"1495042568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHMP\" target=\"_blank\">CHMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268189-european-advisory-committee-rejects-ab-sciences-masitinib-marketing-application-for\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory committee rejects AB Science&#39;s masitinib marketing application for mastocytosis; shares down 26%</a></h4><ul><li>The European Medicines Agency's Committee for Medicinal Products for Human Use (<a href='https://seekingalpha.com/symbol/CHMP' title='Champion Industries, Inc.'>OTC:CHMP</a>) adopts a <a href=\"https://seekingalpha.com/pr/16836443-ab-science-announces-chmp-adopted-negative-opinion-masitinib-indolent-systemic-mastocytosis\" target=\"_blank\">negative opinion</a> regarding AB Sciences' (<a href='https://seekingalpha.com/symbol/ABSCF' title='AB Science, Paris'>OTCPK:ABSCF</a> <font color='red'>-26.3%</font>) marketing application seeking approval of masitinib for the treatment of adult patients with smoldering or indolent systemic severe mastocytosis who have not responded to other treatments.</li><li>CHMP was concerned about the reliability of clinical trial results after on-site inspections revealed \"serious failings\" in the way the study was conducted. Also, major changes were made in the study design while it was in process which made the data difficult to interpret. Safety data were limited and there were concerns about the drug's side effects.</li><li>The company says it will ask for a re-examination of the application.</li><li>Masitinib is an orally available tyrosine kinase inhibitor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268189\" data-linked=\"European advisory committee rejects AB Science&#39;s masitinib marketing application for mastocytosis; shares down 26%\" data-tweet=\"$CHMP $CHMP $ABSCF - European advisory committee rejects AB Science&#39;s masitinib marketing application for mastocytosis; shares down 26% https://seekingalpha.com/news/3268189-european-advisory-committee-rejects-ab-sciences-masitinib-marketing-application-for?source=tweet\" data-url=\"https://seekingalpha.com/news/3268189-european-advisory-committee-rejects-ab-sciences-masitinib-marketing-application-for\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268188\" data-ts=\"1495042303\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CXW\" target=\"_blank\">CXW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268188-prison-stocks-punished-on-white-house-woes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prison stocks punished on White House woes</a></h4><ul><li>Corecivic (NYSE:<a href='https://seekingalpha.com/symbol/CXW' title='CoreCivic, Inc.'>CXW</a>) and GEO Group (NYSE:<a href='https://seekingalpha.com/symbol/GEO' title='The GEO Group, Inc.'>GEO</a>) have been big beneficiaries of the law and order promises/actions of the president and his attorney general.</li><li>But CXW is<font color='red'> lower by 10%</font>&nbsp;today, and GEO&nbsp;<font color='red'>7.7%</font>&nbsp;as the future of the Trump administration (or at least its agenda) is <a href=\"https://seekingalpha.com/news/3268097-banks-lead-early-declines-d-c-lines-trump\" target=\"_blank\">being called into</a> question.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268188\" data-linked=\"Prison stocks punished on White House woes\" data-tweet=\"$CXW $CXW $GEO - Prison stocks punished on White House woes https://seekingalpha.com/news/3268188-prison-stocks-punished-on-white-house-woes?source=tweet\" data-url=\"https://seekingalpha.com/news/3268188-prison-stocks-punished-on-white-house-woes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268184\" data-ts=\"1495040994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWW\" target=\"_blank\">WWW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268184-baird-upgrade-lifts-wolverine-world-wide\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird upgrade lifts Wolverine World Wide</a></h4><ul>     <li>Wolverine World Wide (NYSE:<a href='https://seekingalpha.com/symbol/WWW' title='Wolverine World Wide Inc.'>WWW</a>) is&nbsp;<font color='green'>up 3.49%</font>&nbsp;after Baird upgrades to Outperform from Neutral.</li>     <li>The Baird team points to Wolverine's efforts to transform itself.</li>     <li>\"We increasingly are impressed by actions to become more consumer-centric, which have the potential to re-ignite top-line growth for WWW's portfolio of well-positioned brands (especially Merrell, Saucony) later in 2017 and into 2018 (targeting sales +mid-single-digits),\" reads the Baird note.</li><li>The Baird <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9480182/doubts-about-wolverine-world-wides-top-line-appear-to-be\" target=\"_blank\">price target</a> on WWW goes to $30.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268184\" data-linked=\"Baird upgrade lifts Wolverine World Wide\" data-tweet=\"$WWW - Baird upgrade lifts Wolverine World Wide https://seekingalpha.com/news/3268184-baird-upgrade-lifts-wolverine-world-wide?source=tweet\" data-url=\"https://seekingalpha.com/news/3268184-baird-upgrade-lifts-wolverine-world-wide\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268183\" data-ts=\"1495040857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268183-financials-top-5-gainers-losers-of-1-05-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:05 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/QIWI' title='QIWI plc'>QIWI</a> <font color='green'>+9%</font>.<a href='https://seekingalpha.com/symbol/PN' title='Patriot National, Inc.'>PN</a> <font color='green'>+7%</font>.</li><li><b>Losers:</b> WAC <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/CXW' title='CoreCivic, Inc.'>CXW</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/GEO' title='The GEO Group, Inc.'>GEO</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SGLB' title='Sigma Labs, Inc.'>SGLB</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/WSR' title='Whitestone REIT'>WSR</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268183\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:05 PM\" data-tweet=\"$CCCR-OLD $QIWI $PN - Financials - Top 5 Gainers / Losers as of 1:05 PM https://seekingalpha.com/news/3268183-financials-top-5-gainers-losers-of-1-05-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3268183-financials-top-5-gainers-losers-of-1-05-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268181\" data-ts=\"1495040815\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UNH\" target=\"_blank\">UNH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268181-unitedhealth-claws-back-from-whistleblower-stoked-sell-off-shares-ahead-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UnitedHealth claws back from whistleblower-stoked sell-off; shares ahead 1%</a></h4><ul><li>The market's sell-off and the weight of a DOJ lawsuit seeking over $1B in restitution sent UnitedHealth Group (<a href='https://seekingalpha.com/symbol/UNH' title='UnitedHealth Group Inc.'>UNH</a> <font color='green'>+0.8%</font>) down 1% at the open, but the stock has recovered as investors take action on the buying opportunity.</li><li>Leerink's Ana Gupte: Decline is overdone. Even if it loses the case, it could be ten years before any payments would made and they would be too small to affect the balance sheet (OUTPERFORM/$210).</li><li>Piper's Sarah James: Decline creates rare opportunity to buy a high-quality insurer. The legal process will take a while to complete (OVERWEIGHT).</li><li>Source: The Fly</li><li>Previously: <a href=\"https://seekingalpha.com/news/3267994-feds-sue-unitedhealth-mischarging\" target=\"_blank\">Feds sue UnitedHealth for mischarging</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3268181\" data-linked=\"UnitedHealth claws back from whistleblower-stoked sell-off; shares ahead 1%\" data-tweet=\"$UNH - UnitedHealth claws back from whistleblower-stoked sell-off; shares ahead 1% https://seekingalpha.com/news/3268181-unitedhealth-claws-back-from-whistleblower-stoked-sell-off-shares-ahead-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3268181-unitedhealth-claws-back-from-whistleblower-stoked-sell-off-shares-ahead-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268180\" data-ts=\"1495040695\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WMT\" target=\"_blank\">WMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268180-wal-mart-unfaltering-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wal-Mart unfaltering into earnings</a></h4><ul><li>Shares of Wal-Mart (NYSE:<a href='https://seekingalpha.com/symbol/WMT' title='Walmart Inc.'>WMT</a>) are hanging on to a slim gain on a solidly down market day after results from Target surprised to the upside.</li><li>Cowen analyst Oliver Chen thinks the Target results bode well for the retail giant from Bentonville.</li><li>What to watch:&nbsp;Consensus estimates on Wal-Mart stand at revenue of $117.63B and EPS of $0.96. Analysts expect U.S. comparable sales to be up 1% during the quarter as pricing initiatives cut into the tally. Any update to Wal-Mart's current FY18 EPS guidance of $4.20 to $4.40 could be critical.</li><li>Wal-Mart is&nbsp;<font color='green'>up 0.19%</font>&nbsp;to $75.25 vs. a 52-week trading range of $62.72 to $77.05.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3268028-target-higher-earnings-beat\" target=\"_blank\">Target higher on earnings beat</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3268180\" data-linked=\"Wal-Mart unfaltering into earnings\" data-tweet=\"$WMT - Wal-Mart unfaltering into earnings https://seekingalpha.com/news/3268180-wal-mart-unfaltering-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3268180-wal-mart-unfaltering-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268173\" data-ts=\"1495039914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268173-healthcare-firms-fail-to-swim-against-tide-all-groups-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare firms fail to swim against the tide; all groups down</a></h4><ul><li>The President Trump-FBI scandal-stoked sell-off has not spared medical firms (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='red'>-1.5%</font>)(<a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a> <font color='red'>-2.9%</font>)(<a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a> <font color='red'>-1.1%</font>)(<a href='https://seekingalpha.com/symbol/IHI' title='iShares U.S. Medical Devices ETF'>IHI</a> <font color='red'>-0.7%</font>). As a consolation, all of the big names are down are light or average volume.</li><li>Representative tickers: (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='red'>-1.7%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='red'>-1.2%</font>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='red'>-1.1%</font>)(<a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='red'>-2.7%</font>)(<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='red'>-1%</font>)(<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='red'>-1%</font>)(<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-0.2%</font>)(<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='red'>-0.6%</font>)(<a href='https://seekingalpha.com/symbol/ABT' title='Abbott Laboratories'>ABT</a> <font color='red'>-0.5%</font>)(<a href='https://seekingalpha.com/symbol/MDT' title='Medtronic plc'>MDT</a> <font color='red'>-0.5%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3268173\" data-linked=\"Healthcare firms fail to swim against the tide; all groups down\" data-tweet=\"$BIIB $IBB $BIB - Healthcare firms fail to swim against the tide; all groups down https://seekingalpha.com/news/3268173-healthcare-firms-fail-to-swim-against-tide-all-groups-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3268173-healthcare-firms-fail-to-swim-against-tide-all-groups-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268176\" data-ts=\"1495039894\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NLY\" target=\"_blank\">NLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268176-only-largest-mortgage-reits-catch-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Only the largest mortgage REITs catch a bid</a></h4><ul><li>Political turmoil surrounding the White House has the major averages&nbsp;<font color='red'>lower by more than 1%</font>, the banks&nbsp;<font color='red'>down nearly 4%</font>, and the 10-year Treasury yield back to its 2017 low.</li><li>Also at its low (or flattest point) for the year is the yield curve, with the 2/10 spread at just over 100 basis points vs. nearly 140 bps at the start of 2017.</li><li>REITs (<a href='https://seekingalpha.com/symbol/IYR' title='iShares U.S. Real Estate ETF'>IYR</a> <font color='green'>+0.5%</font>) are modestly higher, but while nearly all mortgage REITs are in the red, investors are putting money into the two sector giants - Annaly Capital (<a href='https://seekingalpha.com/symbol/NLY' title='Annaly Capital Management, Inc.'>NLY</a> <font color='green'>+0.8%</font>) and AGNC Investment (<a href='https://seekingalpha.com/symbol/AGNC' title='AGNC Investment Corp.'>AGNC</a> <font color='green'>+0.5%</font>).</li><li>ETFs: <a href='https://seekingalpha.com/symbol/MORL' title='UBS ETRACS Monthly Pay 2x Leveraged Mortgage REIT ETN'>MORL</a>, <a href='https://seekingalpha.com/symbol/REM' title='iShares Mortgage Real Estate Capped ETF'>REM</a>, <a href='https://seekingalpha.com/symbol/MORT' title='VanEck Vectors Mortgage REIT Income ETF'>MORT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3268176\" data-linked=\"Only the largest mortgage REITs catch a bid\" data-tweet=\"$NLY $IYR $NLY - Only the largest mortgage REITs catch a bid https://seekingalpha.com/news/3268176-only-largest-mortgage-reits-catch-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3268176-only-largest-mortgage-reits-catch-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268172\" data-ts=\"1495039224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268172-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a> <font color='green'>+32%</font>. <a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/RRGB' title='Red Robin Gourmet Burgers, Inc.'>RRGB</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/QIWI' title='QIWI plc'>QIWI</a> <font color='green'>+8%</font>.</li><li><b>Losers:&nbsp;</b><a href='https://seekingalpha.com/symbol/BEBE' title='bebe stores, inc.'>OTC:BEBE</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/CUO' title='Continental Materials Corp'>CUO</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/ONS-OLD' title='Oncobiologics'>ONS-OLD</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/OHGI' title='One Horizon Group, Inc.'>OHGI</a> <font color='red'>-13%</font>. WAC <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/DELT' title='Delta Technology Holdings Limited'>DELT</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/FRTA' title='Forterra'>FRTA</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/BZUN' title='Baozun'>BZUN</a>&nbsp;<font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268172\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SNDX $CETX $CCCR-OLD - Midday Gainers / Losers https://seekingalpha.com/news/3268172-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3268172-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268175\" data-ts=\"1495038501\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SM\" target=\"_blank\">SM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268175-sm-energy-price-target-trimmed-10-baird-after-yanking-bakken-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SM Energy price target trimmed by $10 at Baird after yanking Bakken sale</a></h4><ul>     <li>SM&nbsp;Energy (<a href='https://seekingalpha.com/symbol/SM' title='SM Energy Company'>SM</a> <font color='green'>+1.8%</font>) is higher even after Baird <a href=\"https://thefly.com/landingPageNews.php?id=2553861&amp;headline=SM-SM-Energy-analyst-commentary-\" target=\"_blank\">lowers its stock price target</a> on to $35 from $45, saying the company's decision to retain its Bakken acreage complicates its earlier corporate goals to focus on the Permian and Eagle Ford areas.</li><li><a href=\"https://seekingalpha.com/news/3267751-sm-energy-pulls-planned-sale-north-dakota-assets\" target=\"_blank\">Yesterday</a>, SM said it was postponing indefinitely its planned sale of the North Dakota assets, as valuations failed to reach its threshold to meaningfully reduce leverage.</li><li>According to TheFly.com, Baird believes the retention pushes out SM's deleveraging goals, though shares remain attractively valued; the firm reiterates its Outperform rating.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268175\" data-linked=\"SM Energy price target trimmed by $10 at Baird after yanking Bakken sale\" data-tweet=\"$SM - SM Energy price target trimmed by $10 at Baird after yanking Bakken sale https://seekingalpha.com/news/3268175-sm-energy-price-target-trimmed-10-baird-after-yanking-bakken-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3268175-sm-energy-price-target-trimmed-10-baird-after-yanking-bakken-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268170\" data-ts=\"1495037568\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URI\" target=\"_blank\">URI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268170-industrials-plunge-on-concerns-over-trump-agenda\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Industrials plunge on concerns over Trump agenda</a></h4><ul><li>The S&amp;P 500 Industrials Index falls as much as 1.7%, as growing concerns around Pres. Trump&rsquo;s administration casts doubt on potential tax reform and infrastructure action.</li><li>Top decliners on the index include United Rentals (<a href='https://seekingalpha.com/symbol/URI' title='United Rentals, Inc.'>URI</a> <font color='red'>-4.9%</font>), American Airlines (<a href='https://seekingalpha.com/symbol/AAL' title='American Airlines Group'>AAL</a> <font color='red'>-3.3%</font>), CSX (<a href='https://seekingalpha.com/symbol/CSX' title='CSX Corporation'>CSX</a> <font color='red'>-2.6%</font>), Union Pacific (<a href='https://seekingalpha.com/symbol/UNP' title='Union Pacific Corporation'>UNP</a> <font color='red'>-2.9%</font>), Snap-On (<a href='https://seekingalpha.com/symbol/SNA' title='Snap-on, Inc.'>SNA</a> <font color='red'>-3.3%</font>) and Rockwell Automation (<a href='https://seekingalpha.com/symbol/ROK' title='Rockwell Automation, Inc.'>ROK</a> <font color='red'>-2.1%</font>).</li><li>Among construction materials companies, Vulcan Materials (<a href='https://seekingalpha.com/symbol/VMC' title='Vulcan Materials Company'>VMC</a> <font color='red'>-3%</font>) and Martin Marietta (<a href='https://seekingalpha.com/symbol/MLM' title='Martin Marietta Materials Inc.'>MLM</a> <font color='red'>-2.5%</font>) are sharply lower.</li><li>The S&amp;P 500 Machinery Index also slides 1.7%, with top decliners  including Stanley Black &amp; Decker (<a href='https://seekingalpha.com/symbol/SWK' title='Stanley Black & Decker, Inc.'>SWK</a> <font color='red'>-1.7%</font>), Caterpillar (<a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a> <font color='red'>-1.2%</font>), Cummins (<a href='https://seekingalpha.com/symbol/CMI' title='Cummins Inc.'>CMI</a> <font color='red'>-2%</font>), Fortive (<a href='https://seekingalpha.com/symbol/FTV' title='Fortive Corporation'>FTV</a> <font color='red'>-1.6%</font>),  Flowserve (<a href='https://seekingalpha.com/symbol/FLS' title='Flowserve Corporation'>FLS</a> <font color='red'>-1.3%</font>) and Parker Hannifin (<a href='https://seekingalpha.com/symbol/PH' title='Parker-Hannifin Corporation'>PH</a> <font color='red'>-1.5%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3268170\" data-linked=\"Industrials plunge on concerns over Trump agenda\" data-tweet=\"$URI $URI $AAL - Industrials plunge on concerns over Trump agenda https://seekingalpha.com/news/3268170-industrials-plunge-on-concerns-over-trump-agenda?source=tweet\" data-url=\"https://seekingalpha.com/news/3268170-industrials-plunge-on-concerns-over-trump-agenda\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>73&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268169\" data-ts=\"1495036832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268169-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul><li><b>Losers:&nbsp;</b><a href='https://seekingalpha.com/symbol/RFP' title='Resolute Forest Products, Inc.'>RFP</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/VRS' title='Verso Corporation'>VRS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/FOXF' title='Fox Factory Holding Corp'>FOXF</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268169\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$RFP $VRS $FOXF - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3268169-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3268169-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268166\" data-ts=\"1495036551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBAC\" target=\"_blank\">SBAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268166-wireless-tower-stocks-riding-high-after-amazon-dish-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wireless tower stocks riding high after Amazon-Dish report</a></h4><ul>   <li>Wireless tower stocks are rising in the face of a down market today after reports that Amazon.com (<a href=\"http://seekingalpha.com/symbol/AMZN\" target=\"_blank\">AMZN</a> <font color='red'>-1.1%</font>) may get involved in a planned Dish Network (<a href=\"http://seekingalpha.com/symbol/DISH\" target=\"_blank\">DISH</a> <font color='green'>+1.7%</font>) <a href=\"https://seekingalpha.com/news/3268091-dish-plus-2_8-percent-said-wireless-network-talks-amazon\" target=\"_blank\">wireless business</a>.</li>    <li>SBA Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/SBAC' title='SBA Communications Corporation'>SBAC</a>) is <font color='green'>up 2.8%</font> to its all-time high; American Tower is <font color='green'>up 2%</font> and also has tagged its all-time high today, and Crown Castle International (NYSE:<a href='https://seekingalpha.com/symbol/CCI' title='Crown Castle International Corp.'>CCI</a>) is <font color='green'>up 2.2%</font> to its highest point since September. The stocks have been climbing with increasing news that industry demand shows no sign of slowing.</li>    <li>Barclays' Amir Rozwadowski has boosted his price target on <a href='https://seekingalpha.com/symbol/AMT' title='American Tower Corporation'>AMT</a> to $140 from $130, implying 7% upside from today's higher price (Source: Bloomberg).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268166\" data-linked=\"Wireless tower stocks riding high after Amazon-Dish report\" data-tweet=\"$SBAC $SBAC $CCI - Wireless tower stocks riding high after Amazon-Dish report https://seekingalpha.com/news/3268166-wireless-tower-stocks-riding-high-after-amazon-dish-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3268166-wireless-tower-stocks-riding-high-after-amazon-dish-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268164\" data-ts=\"1495035969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DWDP\" target=\"_blank\">DWDP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268164-dupont-dow-win-conditional-merger-approval-from-brazil-regulator\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DuPont, Dow win conditional merger approval from Brazil regulator</a></h4><ul>     <li>Brazil's antitrust regulator <a href=\"https://seekingalpha.com/pr/16836290-dow-dupont-receive-conditional-regulatory-approval-brazil-proposed-merger-equals\" target=\"_blank\">approves</a> the planned merger of Dow Chemical (DOW <font color='red'>-2.2%</font>) and DuPont (DD <font color='red'>-2%</font>), conditioned on a divestment plan that includes Dow's Brazilian corn seed business.</li><li>The regulator calls for divestment of a select portion of Dow  AgroSciences' corn seed business in Brazil, including some seed  processing plants and seed research centers, a copy of Dow AgroSciences'  Brazilian corn germplasm bank and a license for the  use of the Dow Seeds brand for a certain period of time.</li><li>The companies call the conditional approval a \"very positive outcome,\" and continue to expect closing the  merger by September 1, with the intended spinoffs to  occur within  18 months of closing.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268164\" data-linked=\"DuPont, Dow win conditional merger approval from Brazil regulator\" data-tweet=\"$DWDP $DD - DuPont, Dow win conditional merger approval from Brazil regulator https://seekingalpha.com/news/3268164-dupont-dow-win-conditional-merger-approval-from-brazil-regulator?source=tweet\" data-url=\"https://seekingalpha.com/news/3268164-dupont-dow-win-conditional-merger-approval-from-brazil-regulator\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268161\" data-ts=\"1495035606\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAPL\" target=\"_blank\">AAPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268161-morgan-stanley-boosts-apple-price-target-seeing-no-iphone-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley boosts Apple price target, seeing no iPhone delay</a></h4><ul>   <li>Apple (<a href=\"http://seekingalpha.com/symbol/AAPL\" target=\"_blank\">AAPL</a> <font color='red'>-2.4%</font>) has gotten a <a href=\"http://www.cnbc.com/2017/05/17/morgan-stanley-apple-iphone-8-isnt-delayed.html\" target=\"_blank\">price target boost</a> from Morgan Stanley, which is bucking rumors by saying it doesn't see any evidence of supply chain delays for the upcoming iPhone.</li>    <li>The firm raised its target to $177, implying 13.8% upside from yesterday's close.</li>    <li>Reports of low yields for components have shaken some investors, but \"Morgan Stanley's Greater China Technology Research colleagues have not yet seen delays in the supply chain and still expect new iPhone production to start on time for most of the components (including OLED),\" the firm says.</li>    <li>It's staying conservative on initial expectations, though, forecasting unit growth of just 3% in the second half vs. 20-30% growth implied in build forecasts.</li>    <li>Meanwhile, the company has begun <a href=\"http://www.cnbc.com/2017/05/17/apple-begins-manufacturing-iphone-se-in-india.html\" target=\"_blank\">making iPhones in India</a> for the first time, with limited production of its iPhone SE in Bengaluru. It expects to start shipping that production to customers in the market this month; the iPhone SE is already available in India.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268161\" data-linked=\"Morgan Stanley boosts Apple price target, seeing no iPhone delay\" data-tweet=\"$AAPL - Morgan Stanley boosts Apple price target, seeing no iPhone delay https://seekingalpha.com/news/3268161-morgan-stanley-boosts-apple-price-target-seeing-no-iphone-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3268161-morgan-stanley-boosts-apple-price-target-seeing-no-iphone-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268153\" data-ts=\"1495034203\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVS\" target=\"_blank\">CVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268153-pharmacy-operators-under-pressure-on-amazon-threat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pharmacy operators under pressure on Amazon threat</a></h4><ul><li>The market's down day notwithstanding, CVS Health (<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a> <font color='red'>-1.5%</font>), Walgreens Boots Alliance (<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a> <font color='red'>-2.8%</font>) and Rite Aid (<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a> <font color='red'>-2%</font>) are all under additional pressure on the rumor that Amazon (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='red'>-1%</font>) is preparing to enter the pharmaceutical market.</li><li>The 800-pound gorilla of e-commerce has hired Mark Lyons from Premera Blue Cross to build an internal pharmacy benefits manager for its employees, according to CNBC. It also recently began selling medical supplies and equipment in the U.S. and is hiring industry talent to ensure that it is meeting regulatory requirements.</li><li>Source: The Fly</li><li>Previously: <a href=\"https://seekingalpha.com/news/3267998-amazon-pharmacy-horizon\" target=\"_blank\">Amazon pharmacy on the horizon</a> (May 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3268153\" data-linked=\"Pharmacy operators under pressure on Amazon threat\" data-tweet=\"$CVS $CVS $WBA - Pharmacy operators under pressure on Amazon threat https://seekingalpha.com/news/3268153-pharmacy-operators-under-pressure-on-amazon-threat?source=tweet\" data-url=\"https://seekingalpha.com/news/3268153-pharmacy-operators-under-pressure-on-amazon-threat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>51&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268149\" data-ts=\"1495033373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTHX\" target=\"_blank\">GTHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268149-g1-therapeutics-debuts-today-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">G1 Therapeutics debuts today at $15</a></h4><ul><li>IPO G1 Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GTHX' title='G1 Therapeutics'>GTHX</a>) is set to begin trading today. It looks like it will open at ~$16, ~7% above its $15 offering price.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3267856-g1-therapeutics-set-100m-ipo\" target=\"_blank\">G1 Therapeutics set for $100M IPO</a> (May 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3268149\" data-linked=\"G1 Therapeutics debuts today at $15\" data-tweet=\"$GTHX - G1 Therapeutics debuts today at $15 https://seekingalpha.com/news/3268149-g1-therapeutics-debuts-today-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3268149-g1-therapeutics-debuts-today-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268129\" data-ts=\"1495033229\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268129-healthcare-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare  Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a> <font color='green'>+56%</font>. <a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/CNCE' title='Concert Pharmaceuticals, Inc.'>CNCE</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/VIVO' title='Meridian Bioscience Inc.'>VIVO</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/XLRN' title='Acceleron Pharma Inc.'>XLRN</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TEAR' title='TearLab Corporation'>TEAR</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268129\" data-linked=\"Healthcare  Gainers / Losers as of 11:00 am\" data-tweet=\"$SNDX $OMER $PULM - Healthcare Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3268129-healthcare-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3268129-healthcare-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268145\" data-ts=\"1495032735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRS\" target=\"_blank\">CHRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268145-abbvies-humira-patent-loss-not-death-blow\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AbbVie&#39;s Humira patent loss not a death blow</a></h4><ul><li>Despite Coherus BioSciences' (<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+8.8%</font>) win in its challenge to a patent covering AbbVie's (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='red'>-2.2%</font>) top seller Humira (adalimumab), the setback should not have much of an impact on the latter's valuation, at least not for several years.</li><li>Leerink's Geoff Porges: \"This brings the likely date of biosimilar launch in the U.S. forward by a year, compared to consensus, and is likely to knock 5-10% from AbbVie&rsquo;s value. This does not mean that Coherus (the petitioner), or Amgen or anyone else can launch tomorrow, but it does trigger a process that is likely to result in launch at least 1 year, and possibly 2 years, earlier than consensus expects.\"</li><li>Evercore ISI's Umer Raffat adds that there is an extensive patent estate covering Humira with many still to be litigated. In addition, AbbVie is entering a \"very data-rich period for its pipeline.\"</li><li>Source: <a href=\"http://www.barrons.com/articles/abbvie-losing-humira-patent-isnt-the-end-1495030486?mod=yahoobarrons&amp;ru=yahoo&amp;yptr=yahoo\" target=\"_blank\">Barron's</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3268145\" data-linked=\"AbbVie&#39;s Humira patent loss not a death blow\" data-tweet=\"$CHRS $CHRS $ABBV - AbbVie&#39;s Humira patent loss not a death blow https://seekingalpha.com/news/3268145-abbvies-humira-patent-loss-not-death-blow?source=tweet\" data-url=\"https://seekingalpha.com/news/3268145-abbvies-humira-patent-loss-not-death-blow\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268144\" data-ts=\"1495032060\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RRGB\" target=\"_blank\">RRGB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268144-shorts-burned-red-robin-gourmet-burgers-skyrockets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shorts burned as Red Robin Gourmet Burgers skyrockets</a></h4><ul> <li>Shorts are getting cooked on Red Robin Gourmet Burgers (<a href='https://seekingalpha.com/symbol/RRGB' title='Red Robin Gourmet Burgers, Inc.'>RRGB</a> <font color='green'>+14.9%</font>) after the company surprised with its Q1 report (<a href=\"http://www.nasdaq.com/symbol/rrgb/short-interest\" target=\"_blank\">Nasdaq short interest report</a>). Management is being lauded by Wall Street analysts for its margin execution in the face of labor pressure.</li> <li>Bank of America Merrill Lynch upgrades the restaurant stock to Buy and lifts its price target all the way up to $80. Morgan Stanley ups its PT to $58 from $53 and Jefferies moves its PT to $61 from $52.</li> <li>CEO Denny Marie Post took a victory lap on the company's earnings call (<a href=\"https://seekingalpha.com/article/4073921-red-robin-gourmet-burgers-rrgb-ceo-denny-marie-post-q1-2017-results-earnings-call-transcript?part=single\" target=\"_blank\">transcript</a>) last night and explained the improved results.</li> <li>\"We reversed and stabilized value perceptions last year and we expect based on traffic trends and menu mix that we are gaining momentum in value perception this year,\" noted Post.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3267920-red-robin-gourmet-burgers-beats-0_32-beats-revenue\" target=\"_blank\">Red Robin Gourmet Burgers beats by $0.32, beats on revenue</a> (May 16)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3267939-red-robin-gourmet-tops-beaten-expectations\" target=\"_blank\">Red Robin Gourmet tops beaten-down expectations</a> (May 16)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268144\" data-linked=\"Shorts burned as Red Robin Gourmet Burgers skyrockets\" data-tweet=\"$RRGB - Shorts burned as Red Robin Gourmet Burgers skyrockets https://seekingalpha.com/news/3268144-shorts-burned-red-robin-gourmet-burgers-skyrockets?source=tweet\" data-url=\"https://seekingalpha.com/news/3268144-shorts-burned-red-robin-gourmet-burgers-skyrockets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268143\" data-ts=\"1495031993\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLUG\" target=\"_blank\">PLUG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268143-plugminus-7-after-downgrade-roth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plug -7% after downgrade at Roth</a></h4><ul><li>Roth Capital has <a href=\"https://www.streetinsider.com/Analyst+Comments/Roth+Capital+Downgrades+Plug+Power+%28PLUG%29+to+Sell%3B+Amazon+Is+Dilutive%2C+Not+Additive/12915634.html\" target=\"_blank\">lowered</a> Plug Power (<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='red'>-7%</font>) from Neutral to Sell, with a price target of $1.30 (from $2.25).</li><li>\"PLUG reported weak 1Q17 earnings....We are downgrading on obvious customer attrition and poor quality of revenue, earnings, and gross margins going forward.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3268143\" data-linked=\"Plug -7% after downgrade at Roth\" data-tweet=\"$PLUG - Plug -7% after downgrade at Roth https://seekingalpha.com/news/3268143-plugminus-7-after-downgrade-roth?source=tweet\" data-url=\"https://seekingalpha.com/news/3268143-plugminus-7-after-downgrade-roth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268141\" data-ts=\"1495031844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268141-yield-curve-flattest-since-election\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yield curve flattest since election</a></h4><ul><li>The gap between the 10-year and 2-year Treasury <a href=\"https://www.ft.com/content/812ce43b-5e76-3e57-b976-c910d6cbd73a\" target=\"_blank\">has narrowed to just over</a> 100 basis points - the lowest since Nov. 8. There's plenty of excitement in markets today to encourage buyers at the long end, but the yield curve has been on a steady flattening trend since late December (it peaked then at about 135 basis points).</li><li>A Fed rate hike in March (and another expected in June), sluggish Q1 growth, and slowing inflation are combining with what's looking like a serious stalling in the tax cut and regulatory reform agenda.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3268106-major-rally-treasurys-trump-agenda-teeters\" target=\"_blank\">Major rally in Treasurys as Trump agenda teeters</a> (May 17)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/IEF' title='iShares 7-10 Year Treasury Bond ETF'>IEF</a>, <a href='https://seekingalpha.com/symbol/PST' title='ProShares UltraShort 7-10 Year Treasury ETF'>PST</a>, <a href='https://seekingalpha.com/symbol/IEI' title='iShares 3-7 Year Treasury Bond ETF'>IEI</a>, <a href='https://seekingalpha.com/symbol/TYO' title='Direxion Daily 10-Year Treasury Bear 3x Shares ETF'>TYO</a>, <a href='https://seekingalpha.com/symbol/UST' title='ProShares Ultra 7-10 Year Treasury ETF'>UST</a>, <a href='https://seekingalpha.com/symbol/DTYS' title='iPath U.S. Treasury 10-Year Bear ETN'>DTYS</a>, <a href='https://seekingalpha.com/symbol/VGIT' title='Vanguard Intermediate-Term Government Bond Index ETF'>VGIT</a>, <a href='https://seekingalpha.com/symbol/STPP' title='iPath U.S. Treasury Steepener ETN'>STPP</a>, <a href='https://seekingalpha.com/symbol/FLAT' title='iPath U.S. Treasury Flattener ETN'>FLAT</a>, <a href='https://seekingalpha.com/symbol/TBX' title='ProShares Short 7-10 Year Treasury ETF'>TBX</a>, <a href='https://seekingalpha.com/symbol/SCHR' title='Schwab Intermediate-Term U.S. Treasury ETF'>SCHR</a>, <a href='https://seekingalpha.com/symbol/ITE' title='SPDR Barclays Intermediate Term Treasury ETF'>ITE</a>, <a href='https://seekingalpha.com/symbol/GSY' title='Guggenheim Enhanced Short Duration ETF'>GSY</a>, <a href='https://seekingalpha.com/symbol/TYD' title='Direxion Daily 10-Year Treasury Bull 3x Shares ETF'>TYD</a>, <a href='https://seekingalpha.com/symbol/DTYL' title='iPath U.S. Treasury 10-Year Bull ETN'>DTYL</a>, <a href='https://seekingalpha.com/symbol/DFVL' title='iPath U.S. Treasury 5-Year Bull ETN'>DFVL</a>, <a href='https://seekingalpha.com/symbol/TBZ' title='ProShares UltraShort 3-7 Year Treasury ETF'>TBZ</a>, <a href='https://seekingalpha.com/symbol/DFVS' title='iPath U.S. Treasury 5-Year Bear ETN'>DFVS</a>, <a href='https://seekingalpha.com/symbol/TYNS' title='Direxion Daily 7-10 Year Treasury Bear 1x Shares ETF'>TYNS</a>, <a href='https://seekingalpha.com/symbol/HYDD' title='Direxion Daily High Yield Bear 2x Shares ETF'>HYDD</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3268141\" data-linked=\"Yield curve flattest since election\" data-tweet=\"$IEF $PST $IEI - Yield curve flattest since election https://seekingalpha.com/news/3268141-yield-curve-flattest-since-election?source=tweet\" data-url=\"https://seekingalpha.com/news/3268141-yield-curve-flattest-since-election\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268138\" data-ts=\"1495031449\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268138-crude-inventories-decline-in-last-week\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude inventories decline in the last week</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories:</a> Crude <strong>-1.8M</strong> barrels vs. -2.4M consensus, -5.2M last week.</li><li>Gasoline <strong>-0.4M</strong> barrels vs. -0.7M consensus, -0.2M last week.</li><li>Distillates <strong>-1.9M</strong> vs. -1.1M consensus, -1.6M last week.</li><li>Futures&nbsp;<font color='green'>+0.23%</font>&nbsp;to $48.77.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3268138\" data-linked=\"Crude inventories decline in the last week\" data-tweet=\"$USO $OIL $UCO - Crude inventories decline in the last week https://seekingalpha.com/news/3268138-crude-inventories-decline-in-last-week?source=tweet\" data-url=\"https://seekingalpha.com/news/3268138-crude-inventories-decline-in-last-week\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268133\" data-ts=\"1495029841\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBMD\" target=\"_blank\">WBMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268133-webmd-up-5-bidding-moves-second-round\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WebMD up 5% as bidding moves into second round</a></h4><ul><li>WebMD (<a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a> <font color='green'>+4.7%</font>) bucks the market's down move. Shares are up on light volume as certain bidders prepare to round two of the auction for the online health information provider. Round one closed last week. According to Dealreporter, management is seeking a 20% premium over the company's current valuation.</li><li>Source: The Fly</li></ul><div class=\"tiny-share-widget\" data-id=\"3268133\" data-linked=\"WebMD up 5% as bidding moves into second round\" data-tweet=\"$WBMD - WebMD up 5% as bidding moves into second round https://seekingalpha.com/news/3268133-webmd-up-5-bidding-moves-second-round?source=tweet\" data-url=\"https://seekingalpha.com/news/3268133-webmd-up-5-bidding-moves-second-round\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268130\" data-ts=\"1495029358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAWW\" target=\"_blank\">AAWW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268130-atlas-air-worldwide-announces-convertible-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atlas Air Worldwide announces convertible offering</a></h4><ul> <li>Atlas Air Worldwide (<a href='https://seekingalpha.com/symbol/AAWW' title='Atlas Air Worldwide Holdings'>AAWW</a> <font color='red'>-5.9%</font>) is down sharply after the company offers up $250M in convertible senior notes.</li> <li>The company plans to use the proceeds to pay off higher-rate revolver borrowings.</li> <li><a href=\"https://seekingalpha.com/pr/16835218-atlas-air-worldwide-offering-convertible-senior-notes\" target=\"_blank\">Source: Press Release</a></li>  </ul><div class=\"tiny-share-widget\" data-id=\"3268130\" data-linked=\"Atlas Air Worldwide announces convertible offering\" data-tweet=\"$AAWW - Atlas Air Worldwide announces convertible offering https://seekingalpha.com/news/3268130-atlas-air-worldwide-announces-convertible-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3268130-atlas-air-worldwide-announces-convertible-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268128\" data-ts=\"1495029087\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTBC\" target=\"_blank\">MTBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268128-debtor-getting-inpatient-medical-transcription-billing-over-5m-debt\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Debtor getting inpatient with Medical Transcription Billing over $5M debt</a></h4><ul><li>In a <a href=\"https://seekingalpha.com/filing/3554808\" target=\"_blank\">regulatory filing</a>, Medical Transcription Billing (<a href='https://seekingalpha.com/symbol/MTBC' title='Medical Transcription Billing'>MTBC</a> <font color='red'>-1.5%</font>) reports that that it expects to receive a letter from Prudential demanding the repayment of $2M of a $5M debt that was due on May 15. The company received a demand letter on March 29 related to $3M.</li><li>The company says it is trying to \"arrive at a mutually agreeable resolution\" of the matter.</li><li>The $5M debt relates to its $7M acquisition of MediGain in October 2016.</li><li>Shares are down on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268128\" data-linked=\"Debtor getting inpatient with Medical Transcription Billing over $5M debt\" data-tweet=\"$MTBC - Debtor getting inpatient with Medical Transcription Billing over $5M debt https://seekingalpha.com/news/3268128-debtor-getting-inpatient-medical-transcription-billing-over-5m-debt?source=tweet\" data-url=\"https://seekingalpha.com/news/3268128-debtor-getting-inpatient-medical-transcription-billing-over-5m-debt\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268127\" data-ts=\"1495028959\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBMD\" target=\"_blank\">WBMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268127-dealreporter-webmd-bidding-process-heating-up-shares-up-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DealReporter: WebMD bidding process heating up; shares up more than 4%</a></h4><ul><li><a href=\"https://twitter.com/search?q=%24wbmd&amp;src=typd\" target=\"_blank\">According to Dealreporter</a>, the auction for WebMD (NASDAQ:<a href='https://seekingalpha.com/symbol/WBMD' title='WebMD Health Corp'>WBMD</a>) has moved past the first round. Their sources say $66 per share will get the deal done.</li><li>Shares&nbsp;<font color='green'>+4.35%</font>&nbsp;to $57.20.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268127\" data-linked=\"DealReporter: WebMD bidding process heating up; shares up more than 4%\" data-tweet=\"$WBMD - DealReporter: WebMD bidding process heating up; shares up more than 4% https://seekingalpha.com/news/3268127-dealreporter-webmd-bidding-process-heating-up-shares-up-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3268127-dealreporter-webmd-bidding-process-heating-up-shares-up-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268125\" data-ts=\"1495028865\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CL\" target=\"_blank\">CL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268125-analysts-weigh-in-on-potential-colgate-palmolive-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts weigh in on potential Colgate-Palmolive deal</a></h4><ul> <li>Colgate-Palmolive (NYSE:<a href='https://seekingalpha.com/symbol/CL' title='Colgate-Palmolive Co.'>CL</a>) <font color='green'>jumps 2.92%</font> in early trading as analysts back the idea of the company selling itself at around $100 per share.</li> <li>Jefferies thinks a potential Colgate deal is a \"once-in-a-lifetime deal\" for Unilever (<a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a>, <a href='https://seekingalpha.com/symbol/UL' title='Unilever Plc'>UL</a>).</li> <li>United First Partners analyst Federico Mennuni thinks the increase in consolidation in the consumer products sector could incentivize Colgate to accept an offer.</li> <li>CL traded as high as $74.29 today.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3267999-colgate-may-looking-sell\" target=\"_blank\">Colgate may be looking to sell</a> (May 17)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268125\" data-linked=\"Analysts weigh in on potential Colgate-Palmolive deal\" data-tweet=\"$CL $CL $UN - Analysts weigh in on potential Colgate-Palmolive deal https://seekingalpha.com/news/3268125-analysts-weigh-in-on-potential-colgate-palmolive-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3268125-analysts-weigh-in-on-potential-colgate-palmolive-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268124\" data-ts=\"1495028801\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268124-disneyminus-1_9-macquarie-cuts-to-neutral-on-espn-worries\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Disney -1.9% as Macquarie cuts to Neutral on ESPN worries</a></h4><ul>   <li>Walt Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) is <font color='red'>off 1.9%</font> as Macquarie downgrades to Neutral on (what else) concerns about ESPN and the company's cable network exposure.</li>    <li>The Mouse House's theme parks, studio and consumer products units are still \"best in in class by a country mile,\" but that's well known and expectations are high, says analyst Tim Nollen. Meanwhile the subscriber declines at ESPN have once again stolen the focus for investors, and valuation imply that Disney's now trading at fair value, he argues.</li>    <li>He's lowered his price target to $105 from $125, vs. the current price of $105.97.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268124\" data-linked=\"Disney -1.9% as Macquarie cuts to Neutral on ESPN worries\" data-tweet=\"$DIS - Disney -1.9% as Macquarie cuts to Neutral on ESPN worries https://seekingalpha.com/news/3268124-disneyminus-1_9-macquarie-cuts-to-neutral-on-espn-worries?source=tweet\" data-url=\"https://seekingalpha.com/news/3268124-disneyminus-1_9-macquarie-cuts-to-neutral-on-espn-worries\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268122\" data-ts=\"1495028546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268122-buy-dip-in-clovis-oncology-jpmorgan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buy the dip in Clovis Oncology - JPMorgan</a></h4><ul><li><a href=\"https://twitter.com/thenotablecalls\" target=\"_blank\">via Notable Calls is a bit more detail </a>on the earlier-reported upgrade from JPMorgan</li><li>The recent 35% decline in Clovis (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>) makes for an enticing entry point ahead of June's binary event - the ARIEL 3 data - says analyst Cory William Kasimov. He's grown increasingly comfortable with ARIEL 3 as more data has emerged from the PARP class.</li><li>Based on JPM's analysis, ARIEL 3 is likely to look similar to Tesaro's NOVA. The value gap between CLVS ($2.2B market cap) and TSRO ($7.8B) could narrow materially should ARIEL 3 hit.</li><li>He upgrades to Outperform with $72 price target, suggesting&nbsp;<font color='green'>45% upside</font>&nbsp;from yesterday's close.</li><li>Shares are&nbsp;<font color='green'>up 2.5%</font>&nbsp;to $50.80 in early action.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268122\" data-linked=\"Buy the dip in Clovis Oncology - JPMorgan\" data-tweet=\"$CLVS - Buy the dip in Clovis Oncology - JPMorgan https://seekingalpha.com/news/3268122-buy-dip-in-clovis-oncology-jpmorgan?source=tweet\" data-url=\"https://seekingalpha.com/news/3268122-buy-dip-in-clovis-oncology-jpmorgan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268120\" data-ts=\"1495028207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADRO\" target=\"_blank\">ADRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268120-aduro-expands-clinical-collaboration-merck-mesothelioma-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aduro expands clinical collaboration with Merck with mesothelioma study</a></h4><ul><li>Aduro Biotech (<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro Biotech'>ADRO</a>) will <a href=\"https://seekingalpha.com/pr/16836061-aduro-biotech-announces-clinical-collaboration-merck-evaluate-combination-aduro-s-crsminus\" target=\"_blank\">collaborate </a>with Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='red'>-0.5%</font>) on a Phase 2 clinical trial assessing CRS-207, its LADD (live, attenuated double-deleted)-based immunotherapy, with Keytruda (pembrolizumab) in patients with treatment-resistant malignant pleural mesothelioma.</li><li>The partnership builds on the companies' previously announced collaboration assessing the combination in a Phase 2 study in gastric cancer.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268120\" data-linked=\"Aduro expands clinical collaboration with Merck with mesothelioma study\" data-tweet=\"$ADRO $ADRO $MRK - Aduro expands clinical collaboration with Merck with mesothelioma study https://seekingalpha.com/news/3268120-aduro-expands-clinical-collaboration-merck-mesothelioma-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3268120-aduro-expands-clinical-collaboration-merck-mesothelioma-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268118\" data-ts=\"1495027718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268118-amdminus-7_8-premarket-amid-early-reaction-to-analyst-day\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD -7.8% premarket amid early reaction to analyst day</a></h4><ul>   <li>Advanced Micro Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) is <font color='red'>7.8% lower</font> premarket as first reactions to its <a href=\"https://seekingalpha.com/news/3267962-amd-declines-comment-intel-license-report-unveils-epyc-server-chip\" target=\"_blank\">analyst day</a> start to roll out.</li>    <li>The stock was cut to Hold at Loop Capital, which joins about a dozen other firms in the Hold zone.</li>    <li>Meanwhile, Phillip Securities has initiated coverage of AMD at Buy, with a price target of $14.50, implying 13.7% upside.</li>    <li>And Rosenblatt reiterated its Buy rating, noting the <a href=\"https://www.streetinsider.com/Analyst+Comments/Advanced+Micro+Devices+%28AMD%29%3A+1+Socket+Should+Beat+2+-+Rosenblatt/12915945.html\" target=\"_blank\">star of the show</a> was the Epyc server CPU roadmap, which analyst Hans Mosesmann notes should disrupt the standard 2-socket data center infrastructure (mainly by virtue of beating Intel configurations with just one socket). His price target is $20.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268118\" data-linked=\"AMD -7.8% premarket amid early reaction to analyst day\" data-tweet=\"$AMD - AMD -7.8% premarket amid early reaction to analyst day https://seekingalpha.com/news/3268118-amdminus-7_8-premarket-amid-early-reaction-to-analyst-day?source=tweet\" data-url=\"https://seekingalpha.com/news/3268118-amdminus-7_8-premarket-amid-early-reaction-to-analyst-day\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>38&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268114\" data-ts=\"1495027467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LULU\" target=\"_blank\">LULU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268114-lululemon-adds-coo-duties-for-cfo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lululemon adds COO duties for CFO</a></h4><ul> <li>Lululemon (NASDAQ:<a href='https://seekingalpha.com/symbol/LULU' title='Lululemon Athletica Inc.'>LULU</a>) appoints Stuart Haselden as its new chief operating officer. Haselden assumes the COO responsibilities immediately in addition to continuing to serve as the company's CFO.</li> <li><a href=\"https://seekingalpha.com/filing/3553914\" target=\"_blank\">SEC Form 8-K</a></li> <li>LULU <font color='red'>-1.28%</font> premarket to $49.40.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3268114\" data-linked=\"Lululemon adds COO duties for CFO\" data-tweet=\"$LULU - Lululemon adds COO duties for CFO https://seekingalpha.com/news/3268114-lululemon-adds-coo-duties-for-cfo?source=tweet\" data-url=\"https://seekingalpha.com/news/3268114-lululemon-adds-coo-duties-for-cfo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268112\" data-ts=\"1495027288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268112-premarket-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:10 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/BEBE' title='bebe stores, inc.'>OTC:BEBE</a>&nbsp;<font color='red'>-20%</font>&nbsp;on latest reads on <a href=\"https://seekingalpha.com/news/3268102-sharp-drop-bebe-stores\" target=\"_blank\">mall traffic</a>.</li><li><a href='https://seekingalpha.com/symbol/BZUN' title='Baozun'>BZUN</a>&nbsp;<font color='red'>-16%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3267975-baozun-eps-line-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/CNCE' title='Concert Pharmaceuticals, Inc.'>CNCE</a>&nbsp;<font color='red'>-10%</font>&nbsp;on FDA placing <a href=\"https://seekingalpha.com/news/3268072-fda-places-concert-pharmas-mid-stage-study-ctpminus-543-hair-loss-disorder-clinical-hold\" target=\"_blank\">clinical study</a> of CTP-543 on hold.</li><li><a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power, Inc.'>PLUG</a> <font color='red'>-9%</font>.</li><li><a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>&nbsp;<font color='red'>-8%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3267962-amd-declines-comment-intel-license-report-unveils-epyc-server-chip\" target=\"_blank\">analyst day</a> presentations.</li><li><a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3268066-american-eagle-outfitters-misses-0_01-beats-revenue\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/LND' title='BrasilAgro - Brazilian Agricultural Real Estate Co ADR'>LND</a> <font color='red'>-6%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3268112\" data-linked=\"Premarket Losers as of 9:10 am\" data-tweet=\"$BEBE $BZUN $CNCE - Premarket Losers as of 9:10 am https://seekingalpha.com/news/3268112-premarket-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3268112-premarket-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268110\" data-ts=\"1495027220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268110-premarket-gainers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:10 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/RRGB' title='Red Robin Gourmet Burgers, Inc.'>RRGB</a> <font color='green'>+15%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3267920-red-robin-gourmet-burgers-beats-0_32-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a> <font color='green'>+15%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/16835882-cemtrex-reports-record-month-new-incoming-orders-21-million-orders-received-april-2017\" target=\"_blank\">receiving</a> more than $21M orders in April.</li><li><a href='https://seekingalpha.com/symbol/QIWI' title='QIWI plc'>QIWI</a> <font color='green'>+10%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3268022-qiwi-beats-0_10-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/JACK' title='Jack In The Box Inc.'>JACK</a> <font color='green'>+10%</font>. on Q1 <a href=\"https://seekingalpha.com/news/3267918-jack-box-beats-0_07-revenue-line\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a> <font color='green'>+7%</font>. on <a href=\"https://seekingalpha.com/news/3268090-coherus-prevails-challenge-abbvie-humira-patent-shares-ahead-8-percent-premarket\" target=\"_blank\">announcing</a>&nbsp;that the U.S. Patent Trial and Appeal Board has ruled in favor of its petitions for Inter Partes review of AbbVie's (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) U.S. Patent No. 8,889,135.</li><li><a href='https://seekingalpha.com/symbol/CBIO' title='Catalyst Biosciences, Inc.'>CBIO</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+5%.</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3268110\" data-linked=\"Premarket Gainers as of 9:10 am\" data-tweet=\"$RRGB $CETX $QIWI - Premarket Gainers as of 9:10 am https://seekingalpha.com/news/3268110-premarket-gainers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3268110-premarket-gainers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268109\" data-ts=\"1495027042\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNC\" target=\"_blank\">GNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268109-gnc-holdings-rallies-after-insider-buying-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GNC Holdings rallies after insider buying action</a></h4><ul> <li>GNC Holdings (NYSE:<a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a>) breaks higher on some insider buying.</li> <li>Interim CEO Bob Moran picked up 300K shares at an average price of $6.69 to boost his position to 953K shares.</li> <li><a href=\"https://seekingalpha.com/filing/3553704\" target=\"_blank\">SEC Form 4</a></li><li>GNC&nbsp;<font color='green'>+4.52%</font>&nbsp;premarket to $7.17.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3268109\" data-linked=\"GNC Holdings rallies after insider buying action\" data-tweet=\"$GNC - GNC Holdings rallies after insider buying action https://seekingalpha.com/news/3268109-gnc-holdings-rallies-after-insider-buying-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3268109-gnc-holdings-rallies-after-insider-buying-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268108\" data-ts=\"1495026901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNDX\" target=\"_blank\">SNDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268108-syndax-advances-study-of-entinostat-and-keytruda-shares-ahead-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Syndax advances study of entinostat and Keytruda; shares ahead 12% premarket</a></h4><ul><li>Thinly traded micro cap Syndax Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SNDX' title='Syndax Pharmaceuticals, Inc.'>SNDX</a>) is up <font color=\"green\">12%</font> premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16835340-syndax-pharmaceuticals-announces-advancement-encore-601-non-small-cell-lung-cancer-patients\" target=\"_blank\">announcement</a> that the non-small cell lung cancer &#40;NSCLC&#41; cohort in its <a href=\"https://clinicaltrials.gov/ct2/show/NCT02909452?term=syndax&amp;rank=2\" target=\"_blank\">ENCORE 601</a> study assessing the combination of entinostat and Merck's Keytruda (pembrolizumab) has met its pre-specified objective response threshold and will proceed into the second stage of the trial. Enrollment will re-open immediately and should be completed in H1 2018.</li><li>The cohort consisted of NSCLC patients who failed to respond to anti-PD-1 or PD-L1 therapy. To advance into the definitive stage of the Phase 2 study, at least 10% (n=2/20) of the participants who failed to respond to PD-1/L1 therapy and at least 23% (n=3/13) of treatment-naive participants needed to demonstrate an objective response (partial or complete) to etinostat + Keytruda treatment.</li><li><a href=\"http://www.syndax.com/pipeline/entinostat/\" target=\"_blank\">Entinostat </a>is an orally available small molecule drug that inhibits an enzyme called histone deacetylase &#40;HDAC&#41; which plays a key role in controlling cell survival, proliferation, angiogenesis (formation of new blood vessels) and immunity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268108\" data-linked=\"Syndax advances study of entinostat and Keytruda; shares ahead 12% premarket\" data-tweet=\"$SNDX - Syndax advances study of entinostat and Keytruda; shares ahead 12% premarket https://seekingalpha.com/news/3268108-syndax-advances-study-of-entinostat-and-keytruda-shares-ahead-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3268108-syndax-advances-study-of-entinostat-and-keytruda-shares-ahead-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268102\" data-ts=\"1495026051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BEBE\" target=\"_blank\">BEBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268102-sharp-drop-for-bebe-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sharp drop for Bebe Stores</a></h4><ul> <li>Shares of Bebe Stores (<a href='https://seekingalpha.com/symbol/BEBE' title='bebe stores, inc.'>OTC:BEBE</a>) are down sharply in premarket trading after investors digest the latest reads on mall traffic.</li> <li>Bebe Stores also released its 10-Q report late yesterday, which contained several references to the negative impact of slow mall traffic.</li> <li>BEBE <font color='red'>-20.65%</font> premarket to $4.15.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3268102\" data-linked=\"Sharp drop for Bebe Stores\" data-tweet=\"$BEBE - Sharp drop for Bebe Stores https://seekingalpha.com/news/3268102-sharp-drop-for-bebe-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3268102-sharp-drop-for-bebe-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268061\" data-ts=\"1495025482\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAH\" target=\"_blank\">CAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268061-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Cardinal Health (NYSE:<a href='https://seekingalpha.com/symbol/CAH' title='Cardinal Health Inc.'>CAH</a>) initiated with Hold rating and $77 price target by Jefferies.</li><li>AmerisourceBergen (NYSE:<a href='https://seekingalpha.com/symbol/ABC' title='AmerisourceBergen Corporation'>ABC</a>) initiated with Hold rating and $95 price target by Jefferies.</li><li>McKesson (NYSE:<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a>) initiated with Hold rating and $153 price target by Jefferies.</li><li>Acceleron Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/XLRN' title='Acceleron Pharma Inc.'>XLRN</a>) initiated with Sell rating and $20 (34% downside risk) price target by Goldman Sachs. Shares down<font color='red'> 6%</font>&nbsp;premarket on light volume.</li><li>BioDelivery Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/BDSI' title='BioDelivery Sciences International, Inc.'>BDSI</a>) upgraded to Overweight with a $4 (105% upside) price target by Cantor Fitzgerald. Catalyst: Bulbuca prescription growth. Shares up&nbsp;<font color='green'>5%</font>&nbsp;premarket on average volume.</li><li>Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>) upgraded to Overweight with a $72 (45% upside) price target by JPMorgan. Shares up&nbsp;<font color='green'>3%</font>&nbsp;premarket on modest volume.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3268061\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$CAH $CAH $ABC - Premarket analyst action - healthcare https://seekingalpha.com/news/3268061-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3268061-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268091\" data-ts=\"1495024988\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268091-dishplus-2_8-said-to-be-in-wireless-network-talks-amazon\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dish +2.8%; said to be in wireless network talks with Amazon</a></h4><ul><li>The talks involve Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) becoming a customer of the wireless network <a href='https://seekingalpha.com/symbol/DISH' title='DISH Network Corporation'>DISH</a> is planning to build, <a href=\"http://www.tvnewscheck.com/article/104189/dish-network-amazon-in-wireless-talks\" target=\"_blank\">reports TVNewsCheck</a>.</li><li>It's unclear if the talks involve an investment by Amazon in Dish Network or its potential wireless business. Dish hopes to make an announcement on a deal with Amazon this week at its annual trade show for its independent satellite retailers.</li><li>A linkup with Amazon would boost to Dish's wireless spectrum hopes. Thus far the company has spent $21B acquiring spectrum, but has no customers and only the vaguest of business plans.</li><li>Dish&nbsp;<font color='green'>+2.8%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3268091\" data-linked=\"Dish +2.8%; said to be in wireless network talks with Amazon\" data-tweet=\"$AMZN $AMZN $DISH - Dish +2.8%; said to be in wireless network talks with Amazon https://seekingalpha.com/news/3268091-dishplus-2_8-said-to-be-in-wireless-network-talks-amazon?source=tweet\" data-url=\"https://seekingalpha.com/news/3268091-dishplus-2_8-said-to-be-in-wireless-network-talks-amazon\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268090\" data-ts=\"1495024671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHRS\" target=\"_blank\">CHRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268090-coherus-prevails-in-challenge-to-abbvie-humira-patent-shares-ahead-8-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coherus prevails in challenge to AbbVie Humira patent; shares ahead 8% premarket</a></h4><ul><li>Coherus BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/CHRS' title='Coherus BioSciences'>CHRS</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on higher-than-normal volume in response to is <a href=\"https://seekingalpha.com/pr/16835394-coherus-biosciences-prevails-135-ipr-decision\" target=\"_blank\">announcement </a>that the U.S. Patent Trial and Appeal Board has ruled in favor of its petitions for Inter Partes review of AbbVie's (NYSE:<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a>) U.S. Patent No. 8,889,135 (the '135 patent).</li><li>The decision invalidates all claims of patent which covered a method of treating rheumatoid arthritis by administering 40 mg of HUMIRA (adalimumab) subcutaneously every 13 - 15 days.</li><li>ABBV is down&nbsp;<font color='red'>2%</font>&nbsp;premarket on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268090\" data-linked=\"Coherus prevails in challenge to AbbVie Humira patent; shares ahead 8% premarket\" data-tweet=\"$CHRS $CHRS $ABBV - Coherus prevails in challenge to AbbVie Humira patent; shares ahead 8% premarket https://seekingalpha.com/news/3268090-coherus-prevails-in-challenge-to-abbvie-humira-patent-shares-ahead-8-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3268090-coherus-prevails-in-challenge-to-abbvie-humira-patent-shares-ahead-8-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268073\" data-ts=\"1495023248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEO\" target=\"_blank\">AEO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268073-american-eagle-outfitters-down-post-q1-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Eagle Outfitters down post Q1 results</a></h4><ul>     <li>American Eagle Outfitters (NYSE:<a href='https://seekingalpha.com/symbol/AEO' title='American Eagle Outfitters, Inc.'>AEO</a>) reports comparable sales rose 2% in <a href=\"https://seekingalpha.com/pr/16835713-american-eagle-outfitters-reports-first-quarter-results-comp-sales-increased-2-percent-six\" target=\"_blank\">Q1</a>.</li>     <li>Gross margin rate decreased 270 bps to 36.5%, due to increased promotional activity and higher shipping costs related to a strong digital business.</li>     <li>SG&amp;A expense rate leveraged 60 bps to 25.6%.</li>     <li>Adjusted operating margin rate fell 220 bps to 5.6%.</li>     <li>Merchandise inventory&nbsp;+9% Y/Y to $364.27M.</li>     <li>Store count +3 Q/Q to 1,053.</li>     <li><b>Q2 Guidance</b>: Comparable-store sales: flat to a low single digit decline; Diluted EPS: ~$0.15 to $0.17.</li>     <li><b>FY2017 Guidance</b>:&nbsp;Capex: $160M to $170M; Store count: 1,042 - 1,062.</li>     <li>AEO&nbsp;<font color='red'>-2.78%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268073\" data-linked=\"American Eagle Outfitters down post Q1 results\" data-tweet=\"$AEO - American Eagle Outfitters down post Q1 results https://seekingalpha.com/news/3268073-american-eagle-outfitters-down-post-q1-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3268073-american-eagle-outfitters-down-post-q1-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268075\" data-ts=\"1495023228\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMY\" target=\"_blank\">HMY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268075-gold-gold-miners-catch-bid-amid-trump-turmoil\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold, gold miners catch a bid amid Trump turmoil</a></h4><ul><li><a href=\"http://www.cnbc.com/2017/05/16/gold-hits-2-week-high-on-trump-concerns-weaker-us-housing-data.html\" target=\"_blank\">Gold grinds higher</a> following reports that Pres. Trump asked the FBI to end its investigation into his former security adviser, <font color='green'>+0.9%</font> at $1,248/oz., a two-week high; silver <font color='green'>+1%</font> at $16.92/oz.</li><li>\"Safe-haven demand because of Trump and geopolitical tensions,  especially arising out of North Korea's missile test, is lifting gold  prices,\" says analyst Barnabas Gan at OCBC.</li><li>Gold miners are broadly higher in premarket trading: <a href='https://seekingalpha.com/symbol/HMY' title='Harmony Gold Mining Company Limited'>HMY</a> <font color='green'>+4%</font>, <a href='https://seekingalpha.com/symbol/AU' title='AngloGold Ashanti Limited'>AU</a> <font color='green'>+3.7%</font>, <a href='https://seekingalpha.com/symbol/KGC' title='Kinross Gold Corporation'>KGC</a> <font color='green'>+2.4%</font>, <a href='https://seekingalpha.com/symbol/IAG' title='IAMGOLD Corporation'>IAG</a> <font color='green'>+2.3%</font>, ABX <font color='green'>+1.6%</font>, <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+1.4%</font>, <a href='https://seekingalpha.com/symbol/GOLD' title='Barrick Gold Corporation'>GOLD</a> <font color='green'>+1.3%</font>, <a href='https://seekingalpha.com/symbol/GG' title='Goldcorp Inc.'>GG</a> <font color='green'>+1.3%</font>, <a href='https://seekingalpha.com/symbol/NEM' title='Newmont Mining Corporation &#40;Holding Company&#41;'>NEM</a> <font color='green'>+1.2%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/GDX' title='VanEck Vectors Gold Miners ETF'>GDX</a>, <a href='https://seekingalpha.com/symbol/NUGT' title='Direxion Daily Gold Miners Index Bull 3x Shares ETF'>NUGT</a>, <a href='https://seekingalpha.com/symbol/AGQ' title='ProShares Ultra Silver ETF'>AGQ</a>, <a href='https://seekingalpha.com/symbol/GGN' title='GAMCO Global Gold, Natural Resources & Income Trust'>GGN</a>, <a href='https://seekingalpha.com/symbol/DUST' title='Direxion Daily Gold Miners Index Bear 3x Shares ETF'>DUST</a>, <a href='https://seekingalpha.com/symbol/SIL' title='Global X Silver Miners ETF'>SIL</a>, <a href='https://seekingalpha.com/symbol/USLV' title='VelocityShares 3x Long Silver ETN'>USLV</a>, <a href='https://seekingalpha.com/symbol/ZSL' title='ProShares UltraShort Silver ETF'>ZSL</a>, <a href='https://seekingalpha.com/symbol/GOEX' title='Global X Gold Explorers ETF'>GOEX</a>, <a href='https://seekingalpha.com/symbol/UGL' title='ProShares Ultra Gold ETF'>UGL</a>, <a href='https://seekingalpha.com/symbol/DGP' title='DB Gold Double Long ETN'>DGP</a>, <a href='https://seekingalpha.com/symbol/UGLD' title='VelocityShares 3x Long Gold ETN'>UGLD</a>, <a href='https://seekingalpha.com/symbol/GLL' title='ProShares UltraShort Gold ETF'>GLL</a>, <a href='https://seekingalpha.com/symbol/DZZ' title='DB Gold Double Short ETN'>DZZ</a>, <a href='https://seekingalpha.com/symbol/SGDM' title='Sprott Gold Miners ETF'>SGDM</a>, <a href='https://seekingalpha.com/symbol/ASA' title='ASA Gold&Precious Metals'>ASA</a>, <a href='https://seekingalpha.com/symbol/DSLV' title='VelocityShares 3x Inverse Silver ETN'>DSLV</a>, <a href='https://seekingalpha.com/symbol/SLVP' title='iShares MSCI Global Silver Miners ETF'>SLVP</a>, <a href='https://seekingalpha.com/symbol/DGL' title='Inv DB Mul-Sec Shs Invesco DB Gold Fund'>DGL</a>, <a href='https://seekingalpha.com/symbol/RING' title='iShares MSCI Global Gold Miners ETF'>RING</a>, <a href='https://seekingalpha.com/symbol/DBS' title='Invesco DB Silver ETF'>DBS</a>, <a href='https://seekingalpha.com/symbol/DGZ' title='DB Gold Short ETN'>DGZ</a>, <a href='https://seekingalpha.com/symbol/DGLD' title='VelocityShares 3x Inverse Gold ETN'>DGLD</a>, <a href='https://seekingalpha.com/symbol/PSAU' title='Invesco Global Gold and Precious Metals Portfolio ETF'>PSAU</a>, <a href='https://seekingalpha.com/symbol/TGLDX' title='Tocqueville Gold Fund No Load'>TGLDX</a>, <a href='https://seekingalpha.com/symbol/USV' title='UBS ETRACS CMCI Silver Total Return ETN'>USV</a>, <a href='https://seekingalpha.com/symbol/UBG' title='UBS ETRACS CMCI Gold Total Return ETN'>UBG</a>, <a href='https://seekingalpha.com/symbol/GDXX' title='ProShares Ultra Gold Miners ETF'>GDXX</a>, <a href='https://seekingalpha.com/symbol/GDXS' title='ProShares UltraShort Gold Miners ETF'>GDXS</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3268075\" data-linked=\"Gold, gold miners catch a bid amid Trump turmoil\" data-tweet=\"$HMY $HMY $AU - Gold, gold miners catch a bid amid Trump turmoil https://seekingalpha.com/news/3268075-gold-gold-miners-catch-bid-amid-trump-turmoil?source=tweet\" data-url=\"https://seekingalpha.com/news/3268075-gold-gold-miners-catch-bid-amid-trump-turmoil\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268072\" data-ts=\"1495022951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CNCE\" target=\"_blank\">CNCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268072-fda-places-concert-pharmas-mid-stage-study-of-ctpminus-543-in-hair-loss-disorder-on-clinical\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA places Concert Pharma&#39;s mid-stage study of CTP-543 in hair loss disorder on clinical hold pending review of non-clinical toxicology studies; shares down 16% premarket</a></h4><ul><li>At the FDA's request, Concert Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/CNCE' title='Concert Pharmaceuticals, Inc.'>CNCE</a>) has to <a href=\"https://seekingalpha.com/pr/16835625-concert-pharmaceuticals-announces-clinical-hold-ctpminus-543-phase-2a-trial\" target=\"_blank\">submit the results</a> of non-clinical toxicology studies for agency review prior to dosing patients in its Phase 2a study of CTP-543 for the treatment of alopecia areata, an autoimmune disorder characterized by hair loss.</li><li>The clinical hold was not unexpected since the FDA had previously informed the company that it needed to review the toxicology data before proceeding. The agency has 30 days from the receipt of Concert's response to notify the company whether the clinical hold is lifted. No safety concerns have been cited.</li><li>Shares are off&nbsp;<font color='red'>16%</font>&nbsp;premarket but only on 350 shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268072\" data-linked=\"FDA places Concert Pharma&#39;s mid-stage study of CTP-543 in hair loss disorder on clinical hold pending review of non-clinical toxicology studies; shares down 16% premarket\" data-tweet=\"$CNCE - FDA places Concert Pharma&#39;s mid-stage study of CTP-543 in hair loss disorder on clinical hold pending review of non-clinical toxicology studies; shares down 16% premarket https://seekingalpha.com/news/3268072-fda-places-concert-pharmas-mid-stage-study-of-ctpminus-543-in-hair-loss-disorder-on-clinical?source=tweet\" data-url=\"https://seekingalpha.com/news/3268072-fda-places-concert-pharmas-mid-stage-study-of-ctpminus-543-in-hair-loss-disorder-on-clinical\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268062\" data-ts=\"1495022296\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268062-square-down-1_3-bull-rings-register\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square down 1.3% as bull rings the register</a></h4><ul><li><font color='green'>Up 49%</font>&nbsp;this year, Square (NYSE:<a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>) has bumped into BTIG's Mark Palmer's $20 price target. He downgrades to Neutral.</li><li>Shares&nbsp;<font color='red'>-1.3%</font>&nbsp;premarket to $20.08.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268062\" data-linked=\"Square down 1.3% as bull rings the register\" data-tweet=\"$SQ - Square down 1.3% as bull rings the register https://seekingalpha.com/news/3268062-square-down-1_3-bull-rings-register?source=tweet\" data-url=\"https://seekingalpha.com/news/3268062-square-down-1_3-bull-rings-register\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}